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ABSTRACT 
 Equine sarcoids are the most common skin tumors of horses.  Despite being such a 
common entity, relatively little is known about many features of sarcoid epidemiology or 
growth.  In addition, due to the detection of Bovine Papillomavirus (BPV) DNA of 2 different 
types, BPV type 1 (BPV1) and BPV type 2 (BPV2), in equine sarcoids BPV has been suggested 
as the causative agent of sarcoid development.  Recently, however, BPV DNA has also been 
detected in other skin conditions of horses; the significance of this is unclear.  Multiple studies to 
learn more about sarcoids were undertaken. 
 To investigate the epidemiology of sarcoids in horses in Western Canada the records of 
five veterinary diagnostic laboratories were searched to identify submissions of sarcoids from 
horses. The submission record and diagnostic reports of 802 separate submissions of equine 
sarcoids were reviewed for age, breed, and gender of the horse and the number, location and 
clinical type of sarcoid.  Based on these submissions, horses of a wide variety of ages and 23 
different equine breeds were affected, within these breeds, Donkeys were overrepresented.  
The presence of BPV was determined by Polymerase Chain Reaction (PCR).  BPV was 
found in 74 of 96 (77.1%) samples, and using Restriction Fragment Length Polymorphism, 
BPV1 and BPV2 were identified in these samples.  BPV2 was present in 59 (79.7%) of these.  
Unlike other areas in the world, in Western Canada, equine sarcoids are most commonly 
associated with BPV2. 
 A second study examined different clinical types of sarcoids to determine if there was 
differential expression of immunohistochemical markers associated with apoptosis, Cleaved 
Caspase 3(ClC3), and antiapoptotic factors, B-Cell Lymphoma 2 (Bcl-2) and Survivin. No 
differences in the expression of any of these markers regardless of BPV type were noted. 
Survivin was expressed in equine sarcoids of all types and increased levels of expression are 
associated with more aggressive clinical behaviour. 
 Finally, the location of BPV DNA was determined in both sarcoids and a variety of non-
sarcoid inflammatory skin conditions of horses, as well as, normal skin.  PCR for BPV DNA was 
performed on 86 skin biopsies from horses with non-sarcoid skin conditions, as well as, normal 
skin.  BPV DNA was present in 41 of 86 biopsies.  These positive samples, in addition to BPV 
positive sarcoid samples from the earlier study, were dissected into tissue compartments using 
laser microdissection followed by 2 forms of BPV DNA amplification, PCR and isothermal loop 
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mediated amplification.  BPV DNA was more often located in the epidermis of non-sarcoid skin 
conditions than in sarcoids. In addition, areas of inflammation within the dermis and epidermis 
were more likely to contain BPV DNA than non-inflamed areas.  These results suggest that while 
BPV is commonly found in equine skin, the location where it is found differs between sarcoids 
and non-sarcoid samples. When BPV DNA was found in non-sarcoid samples, it was commonly 
associated with inflammation suggesting that microscopic damage to the epidermal barrier of the 
skin maybe an adequate predisposing factor to the development of sarcoids.   
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1. INTRODUCTION AND REVIEW OF THE LITERATURE 
 
1.1 Introduction 
1.1.1 Context 
Sarcoids are neoplasms of dermal fibroblasts in ungulates, especially horses and other 
equids, including donkeys, mules and zebras (Jackson, 1936;Kidney and others, 2001;Lohr and 
others, 2005;Martens and DeMoor, 1996;Ragland, Keown, and Spencer, 1970;Reid and others, 
1994).  They are the most common neoplasm reported in these species (Marais and others, 
2007;Reid and others, 1994;Valentine, 2006).  The term sarcoid was first used to describe these 
neoplasms in 1936, in South Africa, and to distinguish them from other fibroblastic skin tumours 
such as fibromas, fibrosarcomas and papillomas (Jackson, 1936).  Since that time, sarcoids have 
been reported worldwide in wild and domesticated equids and a large variety of horse breeds 
(Bloch, Breen, and Spradbrow, 1994;Borzacchiello and others, 2008;Chambers and others, 
2003;Valentine, 2006). 
The initial description depicted a sarcoid as “a unique locally invasive, benign neoplastic 
like tumour of the skin with a variable epidermal component which has a high propensity for 
recurrence” (Jackson, 1936).  The invasive nature of sarcoids and their tendency to recur 
following treatment remain defining features of sarcoids today (Bogaert and others, 
2008;Knottenbelt, 2005;Ragland, Keown, and Spencer, 1970). An individual horse may have a 
single sarcoid but, more frequently, horses have multiple lesions and hundreds of lesions per 
animal have been reported (Bogaert and others, 2007;Nasir and Campo, 2008). Sarcoids can 
occur over any area of the body, but have a predilection for the region around the genitalia, the 
chest, abdomen and around the head (Angelos and others, 1988;Voss, 1969).  Sarcoids generally 
do not metastasize, but their proliferative and invasive growth can lead to disfigurement, pain, 
and functional impairment (Bogaert and others, 2008).   
Currently there is no universally effective treatment for sarcoids and recurrence following 
treatment is common (Bogaert and others, 2008;Knottenbelt, 2005).  As a result, the presence of 
sarcoids may lead to the “failure” of the animal during a pre-purchase exam and may result in 
exclusionary clauses for loss of use or veterinary fee limitations on insurance policies 
(Knottenbelt, 2005;Nasir and Campo, 2008).   
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1.1.2 Clinical types of sarcoids   
The growth pattern and clinical appearance of sarcoids can vary greatly amoung horses 
and amoung individual lesions (Knottenbelt, 2005).  Based on their clinical appearance, six 
different types of sarcoids have been described (Table 1.1) (Knottenbelt, 2005). While five types 
of sarcoids are commonly reported, the malevolent type has only been reported by one group 
(Knottenbelt and Kelly, 1995).  The typical histologic appearance of sarcoids is a proliferation of 
whorls and interlacing bundles of spindle shaped fibroblasts in the dermis, with epidermal 
hyperkeratosis, hyperplasia, and rete peg formation. Frequently, these fibroblasts grow in a 
perpendicular “picket fence” arrangement to the epidermal basement membrane along the dermal 
epidermal junction (Pascoe and Knottenbelt, 1999).  The mitotic rate is typically low (Goodrich 
and others, 1998).  While increased numbers of dermal fibroblasts are common to all clinical 
types, the other histologic changes are not consistently seen.  The different clinical types cannot 
be distinguished based on their histologic appearance (Martens and others, 2000). 
Sarcoid diagnosis is most commonly made on the basis of clinical appearance, or 
histopathologic examination of biopsy specimens (Martens and others, 2000).  However, 
variability of clinical appearance and the common presence of ulceration, inflammation and 
secondary infection may hinder making a definitive diagnosis. As an additional diagnostic test, 
the presence of Bovine papillomavirus (BPV) as demonstrated by in situ hybridization (ISH) is 
sometimes used (Angelos and others, 1991;Martens and others, 2000), but this, as will be 
described later, may be problematic.      
 
1.1.3 Sarcoid prevalence 
Although, sarcoids are the most common skin tumour of horses representing over 50% of 
all skin tumours (Marti and others, 1993;Pascoe and Summers, 1981;Valentine, 2006), it is 
unclear what the true prevalence of sarcoids is in the horse population.  The reported prevalence 
varies widely depending on the study population examined.  For example, the reported 
prevalence in horses admitted to veterinary hospitals varies from 0.6% to 2% (Angelos and 
others, 1988;Mohammed, Rebhun, and Antczak, 1992), while prevalence based on samples of 
equine origin submitted to diagnostic laboratories was reported to be 15.18% in the Pacific 
northwest of the United States (Valentine, 2006).  Estimation of the relative frequency of the 
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various clinical types of sarcoid is even more difficult to determine.  This estimation is hampered 
in large part by the variability in the severity of disease caused by sarcoids, and the tendency for 
sarcoids to transform to a more aggressive type following surgical intervention.  This may mean 
that small, inoffensive lesions are treated with benign neglect and may not be reported to 
veterinarians (Scott D.W. and Miller W.H., 2003).  Occult and small verrucose sarcoids often do 
not cause clinically significant disease, and as such, they are often overlooked or not treated 
(Pascoe and Knottenbelt, 1999).  Conversely, horses with large, aggressive fibroblastic sarcoids 
are much more likely to receive treatment or biopsy.  As a result, the larger and more aggressive 
types are likely overrepresented in clinical or diagnostic centre populations, while the smaller, 
more benign lesions are likely underrepresented (Scott D.W. and Miller W.H., 2003). 
 
1.2 Risk factors for sarcoid development 
1.2.1 Age 
The risk factors for development of sarcoids are not fully understood.  Horses of almost 
any age may develop sarcoids, but most reports suggest that sarcoids are most commonly seen in 
young horses with a peak incidence somewhere between three and six years (Brostrom, 
1995;Scott D.W. and Miller W.H., 2003).  However, one  study stated that the incidence of 
sarcoids increases in horses until 15 years of age and then decreases thereafter (Mohammed, 
Rebhun, and Antczak, 1992).  Why younger horses are at increased risk of developing these 
tumours is unclear, but it has been suggested that sarcoids may be caused by infection with a 
virus and that as horses age they are likely to develop immunity to this virus. 
 
1.2.2 Gender 
Most studies do not identify any gender predilection for sarcoid development.  Where a 
gender predisposition has been reported, geldings have been at an increased risk compared to 
stallions and mares (Mohammed, Rebhun, and Antczak, 1992;Reid and others, 1994).  Although 
it has been suggested that castration may place geldings at an increased risk for sarcoid 
development (Reid and Mohammed, 1997), this remains unproven and seems unlikely as the 
actual surgical site is rarely affected. 
 
1.2.3 Breed 
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Breed predispositions to sarcoid development have been shown in several studies.  
Studies in the United States have demonstrated that Quarter Horses, Arabians and Appaloosas 
are roughly twice as likely to develop sarcoids as compared to Thoroughbreds (Angelos and 
others, 1988;Mohammed, Rebhun, and Antczak, 1992).  Further, Thoroughbreds are roughly 
twice as likely to develop sarcoids as Standardbreds (Brostrom, 1995;Meredith and others, 
1986;Mohammed, Rebhun, and Antczak, 1992).  The reason for this predisposition is not known, 
but it has been suggested that Quarter Horses and Appaloosas are more likely to be in contact 
with cattle and thus more likely to be in contact with BPV (Mohammed, Rebhun, and Antczak, 
1992).  Alternatively, it may be that these breeds are more likely to work on rough surfaces and 
thus more likely to develop wounds to the legs (Brostrom, 1995).  In addition to lifestyle factors, 
differences in the genetic makeup of these various breeds may contribute to the differences in 
susceptibility to development of sarcoids. 
 
1.2.4 Immune system and equine leukocyte antigens 
 The immune system may play a role in the development of sarcoids.  In Arabian horses, a 
defective DNA protein kinase subunit (DNA-PKcs) that is associated with severe combined 
immunodeficiency is also associated with an increased risk of sarcoid development (Ding and 
others, 2002).  Genetic variation based differences in susceptibility to sarcoid formation may also 
be due to expression of various equine leukocyte antigens (ELA) (Lazary and others, 1985).  
ELA are serologically identifiable gene products of the Major Histocompatability Complex 
(MHC) which are involved in the immune response.  Of these, ELA in two different classes have 
been associated with sarcoid formation (Brostrom and others, 1988;Brostrom, 1995;Gerber, 
Dubath, and Lazary, 1988;Lazary and others, 1985;Meredith and others, 1986).  Class 1 ELA 
genes encode proteins that are present on the surface of all nucleated cells.  ELA of this class that 
are associated with an increased risk of sarcoid formation include: W11 in Irish Warmbloods 
(Lazary and others, 1985), W5 in Swiss and French Warmbloods (Lazary and others, 1985), A5, 
W20 in Swiss Warmbloods (Gerber, Dubath, and Lazary, 1988).  A5 has also been associated 
with the early onset of sarcoid formation (Brostrom, 1995).  Class 2 ELA genes encode proteins 
that are expressed on the surface of antigen presenting cells and the expression of W13 (formerly 
called W3,B1) is strongly associated with increased risk of sarcoid formation in Swiss and Irish 
Warmbloods, Thoroughbreds, Swedish Halfbreds and the Selle Francais (Brostrom and others, 
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1988;Brostrom, 1995;Gerber, Dubath, and Lazary, 1988;Meredith and others, 1986).  
Standardbred horses do not express W13 and this has been suggested as a possible explanation 
for the lower frequency of sarcoids in this breed (Meredith and others, 1986).  However, the 
expression of W13 alone is not sufficient to explain sarcoid formation, as large numbers of 
horses express W13, but most do not develop sarcoids, and horses that do not express W13 may 
develop sarcoids. 
 
1.3 Etiologic agents in sarcoid development 
1.3.1 Early studies 
In early studies, the pattern of horses that developed sarcoids suggested the possibility of 
an infectious agent being the cause of sarcoids (Jackson, 1936). Voss et al. were able to transmit 
sarcoids between naturally affected horses and non-affected horses by transmission of whole 
sarcoid material or cell-free supernatant fluid (Voss, 1969).  Viral agents were deemed to be the 
most likely etiology for sarcoid formation.  Several viruses have been proposed as the causative 
agent, including a retrovirus and two papillomaviruses, one equine and one bovine. 
 
1.3.2 Attempts to transmit sarcoids 
In 1951, Olsen and Cook inoculated biopsy material from the affected skin of cattle with 
active papillomaviral infections into the skin of horses (Olson and Cook, 1951).  These horses 
developed “sarcoma-like” tumours that did not involve the epithelium, often recurred after 
resection and tended to resolve spontaneously.  Replication of these findings was attempted in 
1969 and although lesions that grossly resembled sarcoids were produced, they were 
histologically distinct (Ragland and Spencer, 1969).  These histologic differences included: no 
change in the overlying epidermis, and the arrangement of fibroblasts to the epidermal basement 
membrane did not show the “picket fence” arrangement commonly seen in sarcoids.  In addition, 
unlike true sarcoids which have a low spontaneous regression rate, all of the induced lesions 
regressed within four to 12 months.  This was attributed to the production of a strong immune 
response to the BPV which is not seen in naturally occurring sarcoids.  Attempts to transmit 
sarcoids by inoculation of sarcoid extracts into horses, donkeys and cattle by this group were 
unsuccessful (Ragland, McLaughlin, and Spencer, 1970). 
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1.4 Bovine papillomavirus 
1.4.1 Detection of BPV 
Three viruses have been considered as possible causative agents of sarcoid formation.  
These included BPV, Equine papillomavirus (EPV) and a retrovirus isolated from sarcoid cell 
culture lines (Cheevers and others, 1982).  However, further research demonstrated that EPV 
DNA could not be found in sarcoids (Postey, Appleyard, and Kidney, 2007), and that the 
retrovirus was an endogenous retrovirus and did not demonstrate transforming activity 
(Cheevers, Fatemi-Nainie, and Anderson, 1986) and thus that neither were involved in sarcoid 
transformation.  Southern blotting had facilitated detection of BPV in some sarcoids (Lancaster, 
Olson, and Meinke, 1977), but results were inconsistent.  Inconsistencies may have resulted from 
the very low levels of virus in sarcoids which may have been undetectable using the Southern 
blotting technique. In the early 1990s, multiple groups detected BPV DNA in sarcoids by the use 
of the more sensitive polymerase chain reaction (PCR) (Otten and others, 1993;Teifke, Hardt M., 
and Weiss, 1994;Teifke and Weiss, 1991).   
 
1.4.2 BPV types 
Papillomaviruses are doubled-stranded DNA viruses and are divided into genera and 
types based on the DNA sequences of their L1 open reading frames (de Villiers and others, 
2004).  Two different BPV have been found in sarcoids – BPV type 1 (BPV1) and BPV type 2 
(BPV2) (Otten and others, 1993;Teifke, Hardt M., and Weiss, 1994;Teifke and Weiss, 1991).  
Recently, a third, a putative new BPV has been recovered from a sarcoid in Brazil (Anjos and 
others, 2010).  Papillomaviral particles have not been found in sarcoids and the papillomaviral 
infection is considered to be non-productive with the papillomavirus existing episomally 
(Goodrich and others, 1998).  Using PCR, BPV DNA has been consistently detected in sarcoids 
worldwide with detection rates varying from 73% to 100% (Bloch, Breen, and Spradbrow, 
1994;Borzacchiello and others, 2008;Carr and others, 2001;Carr and others, 2001;Teifke, Hardt 
M., and Weiss, 1994).  Both BPV1 and BPV2 are δ papillomaviruses causing fibropapillomas in 
their natural host – cattle (Nasir and Campo, 2008).  A recent study using quantitative PCR 
demonstrated a positive correlation between  increasing BPV viral load and increasing speed of 
tumour growth (Haralambus, Klukowskarutzler, and Brandt, 2010).  Papillomaviruses are 
typically species specific, with the exception of BPV1, BPV2 (Nasir and Campo, 2008), and 
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possibly the feline sarcoid-associated papillomavirus (Munday, Knight, and Howe, 2010).  BPV1 
has been the papillomavirus most consistently found in sarcoids, present in over 90% of sarcoids 
from Europe (Angelos and others, 1991;Otten and others, 1993;Teifke, Hardt M., and Weiss, 
1994), as compared to the Western United States where BPV2 is the dominant type, being 
identified in 63% of sarcoids (Carr and others, 2001). 
 
 
1.4.3 BPV transforming genes 
1.4.3.1 E5 gene 
Papillomaviruses encode three transforming oncoproteins called early protein 5 (E5), E6 
and E7 (Nasir and Campo, 2008).  E5 and E6 are the major transforming proteins, with E7 
having a complementary role to enhance the transformative abilities of E5 and E6 (DeMasi and 
others, 2007).  The mechanism by which E5 transformation of cells occurs appears to be 
primarily through activation of the platelet derived growth factor (PDGF) β receptor (Petti and 
DiMaio, 1994;Petti, Nilson, and DiMaio, 1991).  In addition, E5 prevents acidification of 
endosomes and Golgi apparatus through binding of the 16kDa subunit of vacuolar H
+ 
ATPase.  
The resultant lack of acidification leads to failure to degrade PDGF receptors.  This in turn 
makes recycling of these undegraded receptors possible, indirectly reducing receptor down-
regulation (Schapiro and others, 2000).  E5 also causes retention of MHC class 1 molecules 
within the Golgi apparatus and prevents their expression on the cell surface, which may allow 
BPV infected cells to evade normal detection and removal by the immune system (Ashrafi and 
others, 2002;Marchetti and others, 2002).  
 
1.4.3.2 E6 gene 
E6 exerts its oncogenic effect in other papillomaviruses by binding to the tumour 
suppressor gene p53 and stimulating its degradation (Scheffner and others, 1990).  However in 
BPV, E6 does not have this binding property (Werness, Levine, and Howley, 1990), and may 
instead exert its effect by sequestering p53 in the cytoplasm of the cell and preventing it from 
functioning by denying p53’s entrance into the nucleus (Nasir and Reid, 1999).  
Immunohistochemical studies on sarcoids have supported this theory by demonstrating p53 in an 
abnormal perinuclear location in 9 to 44% of the sarcoids examined (Martens and others, 
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2000;Nixon and others, 2005).  In addition to its effects on p53, E6 in BPV1 has been shown to 
interact with a cellular adhesion protein called paxillin (Tong and Howley, 1997;Wade, Brimer, 
and Vande, 2008).  This interaction between E6 and paxillin leads to the disruption of the actin 
cytoskeleton of cells, a change characteristic of transformed cells (Tong and Howley, 1997). 
 
1.4.3.3 E7 gene 
The mechanism by which E7 contributes to sarcoid formation is not as clear as those of 
E5 and E6.  E7 alone is not able to transform cells.  Rather, its presence seems to be required for 
full expression of the transforming abilities of E5 and E6 (DeMasi and others, 2007).  More 
specifically, E7 appears to enhance the survivability of transformed cells.  It does this through 
inhibition of anoikis, an apoptosis pathway associated with cell detachment.  BPV transformed 
cells expressing E7 show increased numbers and sizes of anchorage independent colonies in cell 
cultures when compared to non-transformed cells (DeMasi and others, 2007).  The mechanism 
by which this occurs is uncertain, but may be related to E7 binding of a cellular protein known as 
p600 (DeMasi and others, 2007). 
 
1.4.3.4 Sequence variants 
A DNA sequence region encompassing portions of the transforming gene E5 and a 
second early gene, E2, is a common target for PCR amplification in sarcoids (Teifke and Weiss, 
1991).  Numerous sequence variants in E5 have been found in sarcoids.  Chambers et al. found 
six different E5 sequences in sarcoids, including three which resulted in sarcoid-specific amino 
acid sequences (Chambers and others, 2003).  Thus far, the significance of these variants is 
unclear.  More recently, sequence variants in the long control region and E2 open reading frame 
of BPV1 in sarcoids, as opposed to these same regions in BPV1 in cattle, have been discovered 
(Nasir and others, 2007).  Comparisons of activity of these sarcoid specific variants in equine 
and bovine cells suggest that these variants have increased activity in equine cells compared to 
bovine cells and, therefore, may represent an adaptation for function in equine cells (Nasir and 
others, 2007).   
 
1.4.4 Diagnosis based on the presence of BPV 
1.4.4.1 Presence of BPV on equine skin 
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The basis of BPV detection as a tool for use in diagnosing sarcoids is founded upon the 
presence of BPV DNA in sarcoids and the lack of BPV DNA in other equine tumours including 
melanomas, papillomas and squamous cell carcinomas (Carr and others, 2001;Carr and others, 
2001;Chambers and others, 2003;Otten and others, 1993).  However, two recent studies have 
shown that BPV DNA can be detected by PCR in locations on the skin of horses apart from 
within the sarcoid itself (Bogaert and others, 2005;Bogaert and others, 2008).  One study found 
that in sarcoid affected horses, BPV could be detected on apparently normal skin, the sarcoid 
surface and from normal skin in contact with the sarcoid (Bogaert and others, 2005).  There was 
no significant difference in detection rates between these sites.  As well, 44% of horses in contact 
with these affected horses were also BPV positive on their skin.  A second study revealed the 
presence of BPV DNA on the normal skin of 57% of tested horses (Bogaert and others, 2008).  
Using PCR, BPV DNA was detected on the apparently normal skin of horses with sarcoids (73% 
of which were positive), horses in contact with horses with sarcoids (30% positive), horses in 
contact with cattle with recent papillomaviral infections (73% positive), and in control horses 
(30%) (Bogaert and others, 2008).  
The risk of aggressive transformation of sarcoids following diagnostic biopsying 
(Knottenbelt and Kelly, 1995) has led to attempts to find alternate methods for the initial 
diagnosis of sarcoids and to determine the prognosis for recurrence following surgery.  These 
attempts include the use of PCR for the detection of BPV on superficial swabs and skin scrapings 
of suspected sarcoids (Martens, De Moor, and Ducatelle, 2001).  Overall, this method had a 
diagnostic sensitivity rate for the detection of BPV of 88% in swabs and 91% in skin scrapings.  
This sensitivity rate was felt to be less than that of clinical diagnosis and the sensitivity was even 
less in occult or nodular sarcoids where the overlying epithelium was intact.  PCR for BPV DNA 
has also been used in an attempt to determine the probability of recurrence of sarcoids following 
their surgical resection (Martens and others, 2001).  Samples from the surgical margins 
following resection were examined using PCR for the detection of BPV DNA.  Increased risk for 
the recurrence of a sarcoid was associated with detection of BPV in the surgical margins. 
 
1.4.4.2 Presence of BPV in other equine skin conditions 
In addition to normal skin, BPV DNA has also been found in inflammatory skin 
conditions of horses without sarcoids (Angelos and others, 1991;Chambers and others, 
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2003;Yuan and others, 2007).  It is unclear where in these biopsies the BPV DNA was located.  
Perhaps based on these findings, BPV is simply a common skin contaminant of horses and the 
presence of its DNA in sarcoids is coincidental rather than causal.  This, in turn, would mean that 
the simple detection of BPV in suspect skin lesions is not sufficient to confirm that these lesions 
are sarcoids. 
 
1.5 Transmission of sarcoids 
Whether sarcoids are a transmissible tumour from one horse to another is unknown.  It 
has been suggested that direct contact between sarcoid affected horses and unaffected horses 
may allow for transmission of sarcoids (Bogaert and others, 2005;Nasir and Campo, 2008).  If 
sarcoids are caused by BPV, perhaps BPV may be transmitted from one horse to another, but the 
method by which BPV is transmitted is currently unknown (Nasir and Campo, 2008).  There is 
no epidemiologic evidence that BPV is transmitted from cattle to horses (Nasir and Campo, 
2008).  It is possible that BPV may be transmitted from one horse to another by direct contact 
between sarcoid affected horses or by fomites (Pascoe and Knottenbelt, 1999).  In addition, one 
study found that face flies (Musca autumnalis) feeding on sarcoid affected horses contained BPV 
DNA identical to that in the sarcoids and may act as vectors for transmission (Kemp-Symond, 
2000).  As yet, these studies are preliminary and no definitive evidence for transmission has been 
published.   
Alternatively, it had been suggested that like some other tumours, sarcoids may be 
transmitted from one animal to another as a result of the direct inoculation of a transformed cell 
line from one horse to the next.  The genome of the transformed cells would be unique to 
inoculated cell lines and distinct from other cells within the horse.  However, this has been 
recently refuted by showing that transformed cells in sarcoids contain DNA of an identical 
genotype to that of other non-sarcoid circulating cells in the blood (Gobeil and others, 2007).   
 
1.6 Treatment 
Surgical excision is the most common treatment for sarcoids, but trauma, including 
surgical intervention, may induce sarcoids to undergo a rapid and invasive growth phase 
(Knottenbelt, 2005;Pascoe and Knottenbelt, 1999), making development of other treatment 
modalities desirable.  
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With the recent widespread use of vaccines to prevent cervical cancer caused by Human 
papillomaviruses (Oaknin and Barretina, 2008), there is increasing interest in the development of 
an analogous vaccine for prevention of sarcoids in horses.  Small scale trials vaccinating sarcoid-
bearing donkeys and horses with chimeric viral particles containing the BPV L1 (late protein) 
and E7 proteins have recently been reported (Ashrafi and others, 2008;Mattil-Fritz and others, 
2008).  Both trials showed trends to increased regression and reduced progression, but the 
numbers were too small in either case to show any statistical significance. 
 
1.7 Conclusion 
Despite sarcoids being the most common tumour of horses with no consistently effective 
treatment and causing significant distress owners, there remains a surprising lack of basic 
information about this neoplasm.  True understandings of the pathogenesis of sarcoids, risk 
factors for their development, prognostic factors for recurrence and if and how transmission 
occurs, are still lacking.  Further research into these and other areas is needed to guide both the 
development of new treatment protocols and new diagnostic methods. 
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Table 1.1 Clinical classification of equine sarcoids based on appearance as described by 
Knottenbelt (Knottenbelt, 2005). 
 
  
Clinical Type of 
Sarcoid 
Appearance 
Occult Variable from a coat colour change to alopecia 
Verrucose Hyperkeratotic, scaly, thickened skin 
Nodular Firm, distinct subcutaneous nodules with no epidermal 
change 
Fibroblastic Ulceration with marked exophytic, proliferative growth 
Mixed Combination of 2 or more of the above types 
Malevolent Extensive infiltration of lymphatics and extension to local 
lymph nodes 
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2. EPIDEMIOLOGY OF EQUINE SARCOIDS IN HORSES IN WESTERN CANADA 
  
  
 Although sarcoids are a very common tumour of horses their descriptive epidemiologic 
features have not been described in Western Canadian horses.  To do this, we collected the 
diagnostic records of sarcoids from multiple veterinary diagnostic centres across Western 
Canada.  The paraffin histologic blocks of a subsample of these sarcoids were selected for further 
study.  In addition to providing information on sarcoids in Western Canada, this study
1
 allowed 
for the collection of the samples of sarcoids that would be used for study throughout the rest of 
the thesis.   
 
 
 
 
 
 
 
 
 
 
1
 Published as Wobeser, B.K., Davies J.L., Hill, J.E., Jackson, M.L., Kidney, B.A., Mayer, M.N., 
Townsend, H.G.G., Allen, A.L. Epidemiology of equine sarcoids in horses in Western Canada. 
Canadian Veterinary Journal. 2010. Used with permission from Stella Wheatley, Assistant 
Managing Editor, Canadian Veterinary Journal. 
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2.1 Abstract 
Sarcoids are the most common tumour of the equine skin.  Although much research has been 
performed on sarcoids in the rest of the world, only one study describing the epidemiologic 
features of sarcoids in Canadian horses has been published.  The records of five veterinary 
diagnostic laboratories in Western Canada were searched to identify submissions of sarcoids 
from horses. The submission record and diagnostic reports of 802 separate submissions of equine 
sarcoids were reviewed for age, breed, and gender of the horse and the number, location and 
clinical type of sarcoid.  From these records, the 307 submissions that were submitted to 
laboratories in Saskatchewan were compared to a reference group to test for breed and gender 
predisposition.  Based on clinical history and lesion descriptions, five clinical types of sarcoids 
were identified. Horses of a wide variety of ages and 23 different equine breeds were affected 
and, within these breeds Donkeys were overrepresented. A second stratified subset of 96 sarcoids 
representing each of five clinical types was selected, the associated formalin-fixed paraffin-
embedded tissues were collected and polymerase chain reaction for a segment of Bovine 
papillomavirus (BPV) DNA was performed on these tissues.  BPV was found in 74 of 96 
(77.1%) samples, and using restriction fragment length polymorphism, BPV Type 1 (BPV1) and 
BPV Type 2 (BPV2) were differentiated in these samples.  BPV2 was present in 59 (79.7%) of 
these.  Unlike other areas in the world, in Western Canada, equine sarcoids are most commonly 
associated with BPV2. 
Key Words: Equine Sarcoid; Bovine Papillomavirus 2; Western Canada.
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2.2. Introduction  
Equine sarcoids are the most common skin tumour of horses and have been found in 
horses worldwide.  A wide variety of other equids including zebras, donkeys and mules have 
been affected (Jackson, 1936;Kidney and Berrocal, 2008;Lohr and others, 2005;Martens and 
DeMoor, 1996;Reid and others, 1994).  The term “sarcoid” was first used to describe these 
tumours in 1936, in South Africa, to distinguish them from other fibroblastic skin tumours such 
as fibromas, fibrosarcomas and papillomas (Jackson, 1936).  Although these tumours do not 
metastasize, they can be invasive, are regarded as cosmetic defects, can become ulcerated and 
infected and, when occurring near the eyes or on the eyelids, can impair vision. The treatment of 
horses for equine sarcoids can represent a considerable expense to horse owners (Nasir and 
Campo, 2008). 
 Descriptive epidemiologic features of equine sarcoids (i.e., age, breed, clinical type, 
location of tumour, presence of multiple tumours) have not been well defined in Canadian horses 
and, as best can be determined, only a single study has been published (Fretz P.B. and Barber 
S.M., 1980).  Regional estimates of sarcoid prevalence based on records from diagnostic centres 
vary considerably depending on the source of samples, from a high of 15.18% of submissions to 
a diagnostic centre (Valentine, 2006) to a low of 0.74% of horses admitted to a veterinary 
hospital (Angelos and others, 1988).  The age at diagnosis in published studies varies with one 
study suggesting that sarcoids rarely develop in animals older than seven years (Bogaert and 
others, 2005),  while a second study, from the Pacific Northwest of the United States determined 
that the mean age at diagnosis was nine years (Valentine, 2006).
 
 Equine sarcoids are associated with the presence of two types of Bovine papillomavirus 
(BPV); BPV-type 1 (BPV1) and BPV-type 2 (BPV2) (Teifke, Hardt M., and Weiss, 1994).  
Much of the work on the molecular pathogenesis of sarcoids has been conducted in Europe and 
performed exclusively on animals from which BPV1 was detected in lesions.  BPV2 is 
reportedly much more common in sarcoids from horses in the Western United States (Carr and 
others, 2001).  It is unknown if the previous results of research on BPV1 associated sarcoids 
applies to those associated with BPV2 (Carr and others, 2001). 
 To address the knowledge gap in the descriptive epidemiology of equine sarcoids in 
horses in Western Canada the following studies were performed.  Evaluation of submission 
records and diagnostic reports from multiple veterinary diagnostic laboratories in Western 
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Canada were used to describe the epidemiologic features of equine sarcoids.  From these records, 
a subset of cases that had been submitted to laboratories in Saskatchewan were compared to a 
reference group to test for breed and gender predisposition. 
A second subset of the most recently submitted cases, stratified by province of origin, and 
representing different clinical types of sarcoids, was selected and the associated formalin-fixed 
paraffin-embedded tissues utilized.   Polymerase chain reaction (PCR) was performed on this 
subset to detect the presence of BPV, and the type of BPV was identified by restriction fragment 
length polymorphism (RFLP) on PCR positive samples.  Confirmation that the PCR product was 
either BPV1 or BPV2 was conducted by nucleotide sequencing on four samples. 
 
2.3 Materials and Methods 
2.3.1 Cases  
  Surgical biopsies of equine sarcoids diagnosed during the 12 year period between 
January 1, 1996, and December 31, 2007, inclusive, were identified by using computer-based 
record searches at five veterinary diagnostic laboratories in Western Canada: IDEXX Reference 
Laboratories Ltd., located in Langley, British Columbia (formerly Central Laboratory for 
Veterinarians), and their associated laboratories in Edmonton and Calgary, Alberta; the 
Department of Veterinary Pathology at the University of Saskatchewan; and Prairie Diagnostic 
Services, Inc. (PDS) in Regina and Saskatoon, Saskatchewan.   For each case, the submission 
records and diagnostic reports were obtained. Formalin-fixed paraffin embedded (FFPE) tissues 
of the most recently submitted samples stratified by region of each the five clinical types of 
sarcoids were retrieved for molecular based testing. 
 Submission records and diagnostic reports for these biopsies were used to determine 
breed, gender, age at the time of submission, number of sarcoids on the animal, location of the 
sarcoids on the animal and in which province the animal was located.  The submitted history, 
gross appearance and information in the biopsy description were used to determine the clinical 
type of sarcoid.  Sarcoids were classified using the clinical classification scheme proposed by 
Knottenbelt (Knottenbelt, 2005) and these included: fibroblastic, nodular, occult, verrucose, 
mixed and malevolent.    
 
2.3.2 Reference population 
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 Data on all equine skin biopsies not diagnosed as sarcoids within the same time period 
were collected from the records of the Department of Veterinary Pathology at the University of 
Saskatchewan, and PDS in Regina and Saskatoon, Saskatchewan. These data served as the 
reference population for identifying potential risk factors associated with the development of 
sarcoids.  Only those sarcoids identified at these same diagnostic laboratories located in 
Saskatchewan were used for these comparisons. 
 
2.3.3 Data Analysis 
 Risk factors considered for associations with the development of sarcoids were as 
follows: gender (gelding, mare, and stallion), age (in years), and breed.  Comparisons of median 
age of horses with different clinical classifications of sarcoids in this study were performed using 
Kruskal-Wallis Equality of Populations rank test and Dunn’s Multiple Comparison Test. Gender 
and breed information on horses diagnosed with one or more sarcoids was compared to this same 
information on horses with other skin conditions diagnosed by Saskatchewan veterinary 
diagnostic laboratories and the reference population were evaluated for these risk factors using a 
χ2 goodness of fit test.  Relative risk of the occurrence of sarcoid in different breeds and genders 
was made based on comparisons with the occurrence in the breed or gender with the lowest risk 
of disease. Significance was set at p<0.05. Analysis was performed with the aid of a statistical 
software package.
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2.3.4 Determination of the presence and type of Bovine papillomavirus 
For each clinical type of sarcoid, the 20 most recently submitted biopsies from horses, 
stratified by province of origin, were selected from the submissions to the various veterinary 
diagnostic centres.  The FFPE tissue blocks from these samples were utilized for PCR as 
previously described (Teifke, Hardt M., and Weiss, 1994).  Briefly, the single primer set that 
amplifies a 244 base pair (bp) sequence spanning portions of the E2 gene, the intergenic spacer 
region and a small portion of the E5 gene of BPV1, or a similarly located 248 bp sequence of 
BPV2, was utilized (Figure 2.1).  Previous studies using this set of primers have identified the 
amplified sequence as the E5- open reading frame (Carr and others, 2001;Kidney and others, 
2001;Teifke and others, 2003), but comparisons to BPV sequence data in GenBank
b
 revealed 
that the above description of the sequence is more correct. 
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  Following amplification, typing of the BPV in the PCR product was performed.  RFLP 
was utilized to distinguish between the two potential virus types (Teifke, Hardt M., and Weiss, 
1994).  The BPV1 amplicon was cleaved using BstXI which cleaves the 244 bp sequence 
between nucleotides 3888 and 3889 into a 130 bp fragment and a 114 bp fragment. The BPV2 
amplicon was cleaved using HinfI which cleaves the 248 bp sequence between nucleotides 3887 
and 3888 to create 2 fragments; 129 bp and 119 bp long.  RFLP was performed in parallel with 
the two different restriction endonucleases.  To confirm that PCR was amplifying BPV, four 
samples of PCR product, two of each, identified as BPV1 and BPV2 by RFLP, were sequenced. 
  
2.4 Results 
 Eight hundred two equine sarcoids were submitted to the veterinary diagnostic 
laboratories during the 12 year time period.  Two hundred thirty one, 378 and 193 samples were 
from horses resident in Alberta, British Columbia and Saskatchewan, respectively.  Four hundred 
ninety five samples were seen by the IDEXX laboratories and 307 were seen by diagnostic 
laboratories in Saskatchewan.  All laboratories received sarcoids from horses in each of the three 
provinces.  Where the number of sarcoids on the animal could be determined, 204 of 722 
(28.7%) animals had multiple sarcoids present at the time of submission. 
Five different clinical types of sarcoids were present in the submitted biopsy samples; the 
malevolent type of sarcoid was not present in any samples.  The most common type of sarcoid 
was the fibroblastic type (Table 2.1). 
Data on the age of horses with each of the five clinical types of sarcoids present in this 
sample are summarized in Table 2.1.  Median ages ranged from five years for fibroblastic 
sarcoids to seven years for occult, nodular and mixed sarcoids.  The median age of horses with 
fibroblastic sarcoids was significantly younger than for horses with mixed, nodular and occult 
types of sarcoids.  
Horses of a wide range of ages were diagnosed with sarcoids.  Comparisons of reference 
groups of horses revealed that the mean age of affected horses was 6.8 years and the range was 
from 0.5 years to 31 years.  Reference population horses that did not have sarcoids had a mean 
age of 8.9 years and the age range was one day to 30 years.  Horses with sarcoids were 
significantly younger than horses whose skin was biopsied for other reasons (p<0.01). 
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The location of 746 sarcoids on the bodies of 686 horses was determined (Table 2.2).  
The most common location from which sarcoids were biopsied was the head with 307, followed 
by the limbs (149), neck and shoulder (116), abdomen (81), axilla and chest (59) and the 
paragenital region (34).  Thirty-eight horses had sarcoids in more than one of these locations. 
The reference group comprised 443 reports from horses with non-sarcoid skin conditions 
diagnosed by Saskatchewan veterinary diagnostic laboratories over the same time period.  The 
307 sarcoids diagnosed in these laboratories in this 12 year period were used as a study group. 
Sarcoids represented 41.9% of all equine skin submissions seen in these laboratories for this 
period of time. 
Twenty-three breeds of horses were affected. The most commonly identified breeds were 
Quarter Horses and Thoroughbreds (Table 2.3).   Breed relative risks for the presence of sarcoids 
in horses diagnosed in Saskatchewan veterinary laboratories as compared to reference population 
horses were determined (Table 2.3).  The breed with the lowest risk of development of sarcoids 
was Warmbloods.  Compared to the risk of development of sarcoids in Warmbloods, one breed 
had a significantly elevated risk, Donkeys (3.1 times more likely to develop, p = 0.01).   
Geldings, mares and stallions were all affected with the most commonly affected horses 
being geldings (Table 2.3).  No significant difference in the risk for the development of sarcoids 
was identified with any of these groups. 
PCR for amplification of BPV was performed on 96 biopsies, selected from veterinary 
diagnostic laboratories across Western Canada, representing each of the five clinical types seen 
(Table 2.4).  BPV DNA was amplified from 74 of 96 biopsies (77%).  RFLP was performed on 
the PCR product from all BPV positive cases and, using this method, 14 of 74 tested BPV1 
positive (19%), 59 of 74 tested BPV2 positive (80%) and one biopsy tested positive for both 
BPV1 and BPV2 (1%).  
 Nucleotide sequencing was performed on two of the BPV1 positive samples and two of 
the BPV2 positive samples.  These sequences were compared to sequences from GenBank using 
the Basic Local Alignment Search Tool (BLAST) (Altschul and others, 1997).  Multiple 
sequence alignments of the entire amplified region were performed using a computer program.
c
  
The two BPV1 positive samples (GenBank accession numbers FJ895875, FJ895876) showed 
greater than 98% identity with the previously described British II BPV1 sequence recovered 
from equine sarcoid in the United Kingdom (accession number AY232263.1) (Chambers and 
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others, 2003) (Figure 2.2).  While BPV2 PCR products from one sarcoid (accession number 
FJ895874) showed 100% identity with the previously described Swiss V sample found in equine 
sarcoids from Switzerland (accession number AY232264.1) (Chambers and others, 2003) 
(Figure 2.3). PCR product from the other Western Canadian sarcoid (accession number 
FJ895877) had over 98% identity with three nucleotide differences from the Swiss V sample.  
 
2.5 Discussion 
 Sarcoids on horses have been described since historical times (Erk, 1976) and have been 
recognized as a clinical entity since 1936 (Jackson, 1936).  Although there has been abundant 
research on sarcoids in Europe and the United States there has not been, until now, an attempt to 
describe the epidemiologic features of sarcoids in horses in Western Canada.  In this study, 802 
horses with sarcoids were identified based on biopsy submission records to multiple veterinary 
diagnostic laboratories in Western Canada. 
 As sarcoids are the most common skin tumour of horses (Scott D.W. and Miller W.H., 
2003;Valentine, 2006), it is not surprising that horses with sarcoids were present in large 
numbers in each of the three provinces that were examined.  Submissions from the largest 
number of horses were from British Columbia (378) followed by Alberta (231) and 
Saskatchewan (193).  According to a 2003 report on horse numbers in Canada, Alberta had the 
largest number of horses with 299,753, British Columbia had 141, 410 and Saskatchewan had 
126, 252 (Evans, 2003).  While results from this study may suggest that sarcoids are more 
common on a per capita basis in British Columbia, the data for this study was derived from 
veterinary practitioner submitted biopsies from horses and the results may be biased based on the 
willingness of owners to spend money on veterinary diagnostic services.  With this in mind, the 
same report states that owners in British Columbia spend an average of $379 annually on 
veterinary care per horse as compared to $255 in Alberta which may explain the apparent 
difference in frequency of diagnosis per capita (Evans, 2003). 
 As noted in other studies on sarcoids, affected horses frequently have multiple sarcoids at 
the time of biopsy (Martens and others, 2001;Torrontegui B.O. and Reid, 1994).  In this study, 
horses with multiple sarcoids present at the time of biopsy represented 28.7% of the submissions.  
In addition, sarcoids composed 41.9% of all biopsies involving equine skin over this same period 
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at Saskatchewan veterinary diagnostic laboratories making them the most frequently diagnosed 
skin condition. 
Of the six different clinical classifications of sarcoids suggested by Knottenbelt 
(Knottenbelt, 2005), five were found within this study (Table 2.1).  No malevolent sarcoids were 
found in this study and this clinical type has only been reported by one group (Knottenbelt and 
Kelly, 1995).  All other clinical types were present in relatively equal proportions with the 
exception of the fibroblastic type which was present at approximately twice the frequency of 
other types.  While this may represent the actual clinical distribution of cases, it may also 
represent the greater frequency with which these larger and more aggressive tumours are likely 
to receive diagnostic attention (Scott D.W. and Miller W.H., 2003). 
Sarcoids may occur on any part of the body and in this study sarcoids were present in 
many different locations (Table 2.2).  The majority of sarcoids occurred on the head, followed by 
the limbs and the neck and shoulder.  This distribution differs from other studies, which found 
the lower abdomen to be the most common region for sarcoids to develop (Brostrom, 1995;Head, 
1965;Torrontegui B.O. and Reid, 1994), but is similar to that of another study (Ragland, Keown, 
and Spencer, 1970).  Interestingly, all of the studies where the abdomen was the most frequent 
location of sarcoid development were from Europe, while the study with findings similar to the 
current study was from the Pacific Northwest of the United States.  It has been postulated that the 
reason for the variability in sites is due to differences in the use of horses in different geographic 
areas with horses in North America being more likely to injure their legs on rough ground than 
are those in Europe (Brostrom, 1995), but this remains speculative and has not been scientifically 
examined. One possible reason for the large number of sarcoids on the head in this study may be 
a result of sampling bias.  The sarcoids included in this study were submitted by veterinary 
practitioners removing these sarcoids from client-owned horses.  It is possible that lesions on the 
head of horses may be more likely to be removed for aesthetic reasons or may interfere with the 
use of the horse more than a similar lesion located on the flank. 
A large number of equine breeds, 23 in total, were diagnosed with sarcoids in this study.  
Several studies have examined relative risk for the development of sarcoids among breeds 
(Angelos and others, 1988;Meredith and others, 1986;Mohammed, Rebhun, and Antczak, 1992).  
Two of these studies found that among horses diagnosed with sarcoids in New York State, 
Quarter Horses were more than twice as likely to develop sarcoids as compared to 
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Thoroughbreds which, in turn, were twice as likely to develop sarcoids as Standardbred horses 
(Angelos and others, 1988;Mohammed, Rebhun, and Antczak, 1992).  In one of these studies, 
Arabians were identified as the breed with the highest risk of sarcoid development, more than 
three times higher than Thoroughbreds (Mohammed, Rebhun, and Antczak, 1992). This breed 
disposition for development of sarcoids was not present in the current study.  Only Donkeys 
were at a statistically significantly higher risk to be diagnosed with a sarcoid (Table 2.3).  The 
increased risk of Donkeys developing sarcoids has not been previously reported.  Warmbloods, 
Standardbreds and Arabians were among breeds at the lowest risk of developing sarcoids in the 
current study.  However, in none of these breeds was the risk reduction statistically significant. 
This difference in results may represent a variation based on the geographic location and genetic 
heritage of the horses involved, but a more likely explanation maybe the reference populations 
used to make these comparisons. The reference population of the earlier study was comprised of 
horses with corneal ulcers, indigestion, carpal bone chip fractures and tendonitis (Angelos and 
others, 1988), while the current study’s reference population was comprised of horses with skin 
conditions other than sarcoids.  
Similarly, the apparent predilection of donkeys for the development of sarcoids may also 
be related to the reference population chosen in the current study.  It may be that donkeys are 
less frequently biopsied for skin disease than are other breeds of horses thus lowering the number 
of donkeys in the reference population and  artificially elevating the risk of donkey sarcoid 
development. 
 Although more geldings than mares or stallions were diagnosed with a sarcoid, in this 
study, no differences in relative risk were noted (Table 2.3).  In previous studies where a gender 
predilection has been shown, geldings have been found to be at an increased risk when compared 
to stallions and mares (Mohammed, Rebhun, and Antczak, 1992;Reid and others, 1994).  In 
these studies, it was suggested that castration surgery is a risk factor for the development of 
sarcoids, but the lack of a gender predilection and the relative rarity of paragenital location of 
sarcoids in this study does not support this conclusion. 
 Sarcoids have been reported to be a disease of young horses (Brostrom, 1995;Scott D.W. 
and Miller W.H., 2003), and in this study, the mean age of horses with sarcoids in the study 
group was significantly younger than those of the reference population, but there was a wide 
range of affected animals from six months to 31 years old.  Of particular note, is that unlike 
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previous reports which suggest that sarcoids rarely develop in horses older than seven years 
(Brostrom, 1995;Foy, Rashmir-Raven, and Brashier, 2002;Miller R.I. and Campbell R.S.F., 
1982;Torrontegui B.O. and Reid, 1994), the median age of all horses in the current study with 
several clinical types of sarcoids (nodular, occult and mixed) was seven years, suggesting that 
half of the horses with this diagnosis were this age or older at the time of diagnosis. Of interest, 
is that the fibroblastic type classification, the most aggressive clinical type, was also the type 
associated with the youngest median age, statistically significantly younger than horses with 
other clinical types (Table 2.1).  It has been suggested that sarcoids develop initially as one of the 
less aggressive types such as occult or verrucose sarcoids and then transform into the more 
aggressive fibroblastic form (Brostrom, 1995;Knottenbelt and Kelly, 1995;Marti and others, 
1993).  If this were the case, it seems counterintuitive that the most aggressive form of sarcoids 
is seen more often in younger horses than are the less aggressive forms from which it may 
derive. 
 BPV has been reported as the cause of equine sarcoids (Otten and others, 1993;Teifke, 
Hardt M., and Weiss, 1994;Teifke and Weiss, 1991) and in this study BPV DNA was amplified 
from 74 of 96 samples tested (77%).  The amplification rates of BPV DNA from sarcoids in 
various studies has ranged from 73 to 100%, with studies with lower identification rates using 
formalin fixed paraffin-embedded samples as in the current study (Bloch, Breen, and Spradbrow, 
1994;Borzacchiello and others, 2008;Carr and others, 2001;Carr and others, 2001;Teifke, Hardt 
M., and Weiss, 1994).  Confirmation that BPV DNA was in fact being detected was conducted 
by sequencing of a small number of randomly chosen DNA products from amplified sarcoid 
samples.  A high degree of identity with BPV previously recovered from equine sarcoids was 
present.  One BPV2 DNA amplicon contained three previously unidentified nucleotide 
variations.  The significance of these changes is uncertain, but nucleotide variation in other 
regions within these genes has been previously found in equine sarcoids (Chambers and others, 
2003). 
BPV was detected in all clinical types of sarcoids examined (Table 2.4). The lowest 
detection rates were in occult sarcoids with 12 of 19 positive (63%).  Whether this represents 
lower levels of BPV in these types of sarcoids or if some of these biopsies were not truly 
sarcoids is unclear.  Occult sarcoids have the most subtle changes histologically of any of the 
sarcoid types and also have the smallest lesions by volume, often confined to a small 
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proliferation of fibroblasts beneath the skin surface. It is possible that some of these lesions were 
misdiagnosed as sarcoids or that the smaller volume of neoplastic tissue in occult sarcoid as 
compared to other types of sarcoids reduces the success of DNA amplification resulting in a 
lower BPV positivity rates in this classification type of sarcoid. 
 The majority of sarcoids with amplified BPV DNA in this study contained solely BPV2 
DNA based on RFLP (59 of 74 samples, 80% of the total).  BPV1 was found as the only 
amplified BPV type in 14 of 74 samples (19%) while a single sample had a superinfection with 
both BPV1 and BPV2 detected.  This is dramatically different from the results of most studies of 
sarcoids.  In Europe, BPV1 accounts for a vast majority of DNA detected with only a small 
number of sarcoids containing BPV2 (Angelos and others, 1991;Otten and others, 1993;Teifke, 
Hardt M., and Weiss, 1994).  Studies in the United States have found BPV1 and BPV2 in 
roughly equal proportions in the Eastern United States (Teifke, Hardt M., and Weiss, 1994), 
while BPV2 predominates in the Western United States representing 63% of the amplified DNA 
(Carr and others, 2001).   No previous studies have found as high a rate of BPV2 infection as this 
current study.  Most of the work conducted on equine sarcoids was performed on horses infected 
with BPV1 rather than BPV2. Although no clinical or pathogenetic differences between infection 
with BPV1 and BPV2 have been reported, no specific research has been published to confirm 
this.  As such, the relevance of studies performed on horses with sarcoids containing BPV1 to 
horses with sarcoids containing BPV2 is not entirely certain (Carr and others, 2001).  
In summary, this study is the largest study of equine sarcoids specifically focused on 
Western Canadian horses.  Sarcoids appear to be a common lesion of the skin of horses in 
Western Canada.  Although sarcoids in horses in Western Canada may seem similar to those 
reported elsewhere in the world, there are several differences in the details.  Specifically, 
donkeys appear to be at an increased risk of sarcoid development, older horses are more 
commonly affected by sarcoids than some previous reports suggest and, perhaps most 
importantly, BPV2, not BPV1 is the predominant viral type detected in sarcoids in these horses.  
More research is needed to determine the importance of BPV2 as a cause of sarcoids and to 
determine if there are different clinical implications in sarcoids caused by BPV2 versus those 
caused by BPV1 or differences in the pathogenesis of these lesions. 
     
2.6 Sources and Manufacturers 
25 
 
 
a
 Stata/IC 10.1 for Windows, StataCorp LP, College Station Texas 
b
 GenBank, National Center for Biotechnology Information, National Institutes of Health, USA 
c
EMMA multiple alignment program, Emboss Version 5.0.0 (http://haruspex.usask.ca/emboss/). 
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Table 2.1. Clinical type of sarcoid and age of sarcoid affected horses based upon biopsy 
submissions to multiple veterinary diagnostic laboratories in Western Canada (n=467). 
 
 Number  Median Age 
(years) 
Minimum Age 
(years) 
Maximum Age 
(years) 
Fibroblastic 145
 
5
a 
0.6 25 
Nodular 104 7 1.0 23 
Occult 72 7 1.1 21 
Verrucose 72 6 0.5 19 
Mixed 74 7 0.8 31 
Malevolent 0 N/A N/A N/A 
 
a
Significantly lower than nodular, occult and mixed types of sarcoids. (p<0.05) 
N/A = Not applicable 
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Table 2.2. Known locations of 1 or more sarcoids on the body of horses in Western Canada.* 
 
Location on Body Number (%) of horses with at 
least 1 sarcoid at a given location 
Head 307 (41.1%) 
Limb 149 (20.0%) 
Neck / Shoulder 116 (15.5%) 
Abdomen   81 (10.9%) 
Axilla / Chest 59 (7.9 %) 
Paragenital 34 (4.6%) 
Total 746 (100%) 
 
*Some horses had sarcoids in more than one location on the body  
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Table 2.3.  Breed and gender of horses with at least one equine sarcoid diagnosed at a veterinary 
diagnostic laboratory in Saskatchewan between January 1, 1996, and December 31, 2007. 
Relative risk of development of a sarcoid is based on comparisons to horses with skin conditions 
other than sarcoids submitted to these laboratories during the same time period. 
 
 
a
Significantly higher relative risk for the development of sarcoids
 Number 
(row %) of 
horses with 
sarcoids 
Number (row 
%) of horses 
with skin 
conditions 
other than a 
sarcoid 
Risk Relative 
Risk 
P-Value 95% 
Confidence 
Interval 
Breed       
Quarterhorse 147 
(46.8%) 
167 (53.2%) 0.47 1.9 0.07 0.87 - 4.04 
Thoroughbred 22   
(46.8%) 
25   (53.2%) 0.47 1.9 0.11 0.91 - 4.39 
Arabian 20   
(31.7%) 
43   (68.3%) 0.32 1.3 0.59 0.60 – 3.05 
Donkey 10   
(76.9%) 
    3   (23.1%) 0.77  3.1
a
 0.01 1.46 – 5.56 
Draft Horse 9   (27.3%) 24   (72.7%) 0.27 1.1 1.00 0.45 - 2.84 
Appaloosa 7   (31.8%) 15   (68.2%) 0.32 1.3 0.74 0.48 - 3.37 
Warmblood 5   (25.0%)   15  (75.0%) 0.25 Reference   
Standardbred 3   (37.5%) 5   (62.5%) 0.38 1.5 0.65 0.45 - 4.24 
Other/unknown        84        146      
Total        307        443      
       
Gender       
Gelding 146 
(42.3%) 
199 (57.7%) 0.42 1.2 0.37 0.76 – 2.14 
Mare 111 
(41.3%) 
158 (58.7%) 0.41 1.1 0.51 0.83 - 1.60 
Stallion 27   
(36.5%) 
47 (63.5%) 0.36 Reference   
Unknown 23    39        
Total          307        443     
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Table 2.4. Type of Bovine Papillomavirus identified in various clinical types of sarcoids 
submitted to multiple veterinary diagnostic laboratories in Western Canada. 
 
Clinical type 
of sarcoid 
Number 
tested by 
PCR 
Number BPV1 
positive (row %) 
Number BPV2 
positive (row %) 
Total number 
BPV positive 
Fibroblastic 20 3   (15.0%) 11   (55.0%) 14   (70.0%) 
Nodular 19 0        (0%) 15   (78.9%) 15   (78.9%) 
Occult 19 4   (21.1%)    8   (42.1%) 12   (63.2%) 
Verrucose 19 4* (21.1%) 15* (78.9%) 18* (94.7%) 
Mixed  19 4   (21.1%) 11   (57.9%) 15   (78.9%) 
Total 96 15* (15.6%) 60* (62.5%) 74* (77.1%) 
 
*One biopsy tested positive for both BPV1 and BPV2. 
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Figure 2.1 Diagrammatic representation of the genome of Bovine papillomavirus type 1 (BPV1).  
Open reading frames of Early genes (E1 to E8) and Late genes (L1 and L2). 
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3. IMMUNOHISTOCHEMICAL EXPRESSION OF CLEAVED CASPASE-3, B- CELL 
LYMPHOMA 2, AND SURVIVIN IN SARCOIDS FROM HORSES 
 
 
 This study used the paraffin histologic blocks acquired for use in the studies described in 
Chapter two.  These blocks contained tissue from sarcoids of different clinical types.  BPV was 
detected using PCR and, when present, BPV type was determined by RFLP. The method by 
which sarcoid tumours actually grow is unknown.  Immunohistochemistry detection of three 
different antigens related to apoptosis was used to test the hypothesis that sarcoids grow by 
evading apoptosis.  We were able to determine that sarcoids express Survivin and that there are 
differences amoung clinical types of sarcoids in the level of Survivin expression.  
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3.1 Abstract 
Sarcoids are the most common tumour of the skin of horses.  Despite being common, much of 
the detail of sarcoid transformation and growth is not understood.  Whether sarcoid growth is 
associated with evasion of apoptosis by neoplastic fibroblasts is currently unknown.  The aims of 
this study were to examine different clinical types of sarcoids and sarcoids associated with 
different Bovine papillomavirus (BPV) types to determine if there was differential expression of 
immunohistochemical markers associated with apoptosis, Cleaved Caspase-3 (ClC3), and 
antiapoptotic factors, B-Cell Lymphoma 2 (Bcl-2) and Survivin.  Seventy-six sarcoids that 
included tumours of five clinical types collected from multiple diagnostic centres in Western 
Canada were used.  All 76 of these tumours were immunohistochemically stained for the 
identification of ClC3 and Survivin, and 66 were stained for Bcl-2.  ClC3 staining was present in 
only small numbers of neoplastic cells in all types of sarcoids. However, a significantly higher 
proportion of cells in fibroblastic type sarcoids had positive staining compared to occult type 
sarcoids.  No differences in the expression of Bcl-2 between clinical types were noted.  All five 
types of sarcoids had Survivin staining of some of the neoplastic cells.  Nodular and fibroblastic 
sarcoids had significantly higher proportions of Survivin staining cells than occult sarcoids.  
There was no relationship between BPV type and the staining characteristics of any of these 
markers. Survivin expression was detected in equine sarcoids and increased levels of expression 
were associated with more aggressive clinical behaviour.   
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3.2 Introduction 
 Sarcoids are fibroblastic tumours of the equine skin and are the most common tumours 
seen in horses (Scott D.W. and Miller W.H., 2003;Valentine, 2006).  Sarcoids have been 
reported in many countries around the world (Bloch, Breen, and Spradbrow, 1994;Borzacchiello 
and others, 2008;Brostrom and others, 1988;Carr and others, 2001;Fretz P.B. and Barber S.M., 
1980;Jackson, 1936) and their existence has been described since ancient times (Erk, 1976). 
Although these tumours typically do not metastasize, they are regarded as cosmetic defects, can 
become ulcerated and infected and, when occurring near the eyes or on the eyelids, can impair 
vision. 
 Six types of sarcoids have been identified based on their clinical appearance: occult, 
verrucose, nodular, fibroblastic, mixed and malevolent (Knottenbelt, 2005).  The first five of 
these are relatively commonly seen (Martens and others, 2000) while the sixth, the malevolent 
type, has only been described by one group (Knottenbelt and Kelly, 1995).  Occult sarcoids are 
the most clinically benign and often appear as an area of hair loss.  The verrucose type, as the 
name implies, is a wart-like growth.  Nodular sarcoids are protuberances beneath an intact 
epithelium.  Fibroblastic sarcoids are the most clinically aggressive, with exophytic, sometimes 
rapid growth, and frequent ulceration.  The final common type of sarcoid is the mixed type 
which exhibits characteristics of two of the previously described types within a single growth or 
contiguous series of growths. 
 Despite being such a common tumour, much of the detail of how dermal fibroblasts 
transform to produce sarcoids is not understood.   The use of molecular diagnostic techniques, 
most particularly polymerase chain reaction (PCR), has identified that Bovine papillomavirus 
(BPV) is commonly associated with equine sarcoids (Carr and others, 2001;Teifke, Hardt M., 
and Weiss, 1994;Teifke and Weiss, 1991;Wobeser and others, 2010). Two types of BPV are 
associated with the development of equine sarcoids, BPV types 1 (BPV1) and 2 (BPV2).  
Currently, no differences in the sarcoids associated with these two types have been published. 
 Growth of a tumour depends upon an increase in the size of neoplastic cells, an increase 
in the number of neoplastic cells or a reduction in the rate at which neoplastic cells die and are 
removed, as individual processes or combined processes.  Sarcoids are tumours of equine dermal 
fibroblasts which are spindle-shaped cells and significant tumour growth due to increase in cell 
size seems unlikely. More likely, tumour growth depends on increases in replicative rate, 
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reduction in cell death rates, or both.  Several studies have examined the replicative rate of 
equine sarcoids as defined by expression of Ki-67, an immunohistochemical marker of cell 
proliferation (Borzacchiello and others, 2008;Martens and others, 2000;Nixon and others, 2005). 
All of these studies found that the replicative rate of sarcoids was low, and in some cases not 
dissimilar to normal equine skin.  
 Evasion of apoptosis is thought to be an important event in Human papillomavirus (HPV) 
induced malignant transformation of cervical epithelial cells (Branca and others, 2005).  Studies 
to examine whether neoplastic fibroblasts in equine sarcoids evade apoptosis by some method 
have not been published.  
 Apoptosis is a well-defined chain of reactions that leads to the orderly death, dismantling 
and removal of senescent or damaged cells.  The ability of neoplastic cells to evade apoptosis 
allows for their continued growth and survival.  Numerous cell markers have been used in both 
human and veterinary medicine to assess apoptosis in tumours.  However, compared to studies in 
cats and dogs, little work has been done on the use of molecular markers in equine neoplasms, 
including sarcoids. 
  There are a variety of immunohistochemical antibodies available to detect markers 
associated with apoptosis.  Cleaved caspase-3 (ClC3) is expressed in cells undergoing apoptosis 
and its frequency can be evaluated in tumours and compared to appropriate normal tissues to 
determine if different levels of apoptosis are present in the tumour. Other genes, such as B-Cell 
Lymphoma 2 (Bcl-2) and Survivin, are not expressed by normal dermal fibroblasts, but are 
expressed in the cells of some tumours; expression of these genes alters normal cellular 
processes allowing these cells to evade the normal apoptotic mechanisms. In addition, expression 
of Bcl-2 and Survivin, as detected by immunohistochemistry, has been found within HPV virally 
induced dysplastic and cancerous cervical lesions of women.  The expression of these markers 
was associated with worsened prognosis and more aggressive clinical tumour type in these 
tumours (Frost and others, 2002;Yaqin, Runhua, and Fuxi, 2007).   
 The aims of this study were to use immunohistochemistry to detect expression of ClC3, Bcl-
2 and Survivin in equine sarcoids and to determine if expression differs with clinical type of 
sarcoid and BPV type within the sarcoid.   
 
3.3 Materials and Methods 
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3.3.1 Cases 
 Formalin-fixed paraffin-embedded (FFPE) biopsy samples of equine sarcoids 
representing each of the five clinical types (occult, verrucose, nodular, fibroblastic and mixed) 
were collected from multiple veterinary diagnostic centres in Western Canada.  These samples 
had been previously diagnosed as being PCR positive or negative for BPV and, where positive, 
the type of BPV had been determined using restriction fragment length polymorphism (RFLP) 
(Wobeser and others, 2010). From biopsies in this collection, the FFPE tissue samples of 
sarcoids of each clinical type were included in this study.  Each of the samples originated from a 
different horse.  All samples had been reviewed and had a histologic appearance consistent with 
an equine sarcoid.  Of the 76 sarcoids examined in this study, 13 were BPV1 positive, 52 were 
BPV2 positive and eleven were BPV negative. 
 
3.3.2 Immunohistochemical staining 
 Expression of ClC3, Bcl-2 and Survivin was evaluated by immunohistochemistry. From 
each FFPE sarcoid sample three 4 μm serial sections were cut; one for each antibody used.  
Staining was performed using a Benchmark staining platform
a
, with BMK iVIEW DAB Paraffin 
detection kits
b
 using a streptavidin-biotin amplification system. Heat-induced epitope retrieval 
consisted of applying cell conditioner #1 to sections. Slides used for antibody staining were 
counterstained with hematoxylin and bluing reagent.  For the detection of Bcl-2, a commercial 
mouse monoclonal antibody
c
 was utilized at a dilution rate of 1:10. Staining for ClC3 was 
performed with a commercial rabbit polyclonal antibody
d
 at a dilution rate of 1:50. The presence 
of Survivin was determined using a commercial rabbit polyclonal antibody
e
 at a dilution rate of 
1:1000.  Only 66 of the 76 samples were stained with antibody to Bcl-2 because of a limited 
quantity of antibody available. 
 
3.3.3 Control Tissues 
 These immunohistochemical markers have not been previously used in FFPE equine 
tissue so positive and negative equine control tissues were chosen based on reported staining 
characteristics in other species.  FFPE control tissues of equine origin including adult haired 
skin, and fetal tissue including thymus, stomach, pancreas and lymph node, were used for each 
staining run of the three antibodies.  Basal epithelial cells of adult haired skin in other species 
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have been shown to express Bcl-2 immunohistochemically (Madewell and others, 1999).  This 
being the case, adult haired equine skin was used as a positive control for this antibody.  Also, in 
the same samples of adult haired skin, dermal fibroblasts are present and these do not stain 
immunohistochemically with Survivin or Bcl-2 in other species (Johnson and Howerth, 
2004;Madewell and others, 1999). Consequently, equine dermal fibroblasts were used as 
negative controls for both Bcl-2 and Survivin.  Based on immunohistochemical staining in other 
species, equine thymus and lymph node were also included as positive controls for Bcl-2 
(Korsmeyer, 1992;Madewell and others, 1999) and Clc3 (Resendes and others, 2004). Equine 
stomach and thymus were included as positive controls for Survivin based on their reported 
staining in other species (Johnson and Howerth, 2004). 
 
3.3.4 Assessment of staining 
Sections of each sarcoid sample were examined in the same manner for antigen 
expression. Stained sections were examined by a single pathologist without knowledge of 
sarcoid classification type or BPV status. Sections were considered positive if specific brown 
intracytoplasmic or intranuclear immunohistochemical staining was observed in neoplastic 
fibroblasts. For each staining batch, the control slide was carefully examined to determine 
staining characteristics.  Then each sarcoid sample in that batch was examined at 200x 
magnification to subjectively identify the area within the neoplasm that exhibited the largest 
concentration of positively staining neoplastic cells, if present.  When positive staining was 
present, five microscopic fields at 400x magnification were selected within the area chosen as 
most intensely stained and 100 neoplastic cells were counted in each field.  The number of 
positively staining neoplastic cells within these 500 cells was recorded and the mean number of 
positively staining neoplastic cells in each sample was determined and recorded as a percentage 
of positively staining cells per field.  If no staining was present in the sample, the sample was 
considered to be negative for staining for that marker and the percentage of positively staining 
cells per field was recorded as zero.  To better define the character of the immunohistochemical 
staining in addition to the number of cells with positive staining, the location within the cell 
(nuclear or cytoplasmic) and staining pattern (diffuse, granular or vesicular) was recorded. 
 
3.3.5 Data Analysis 
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 For each of the antibodies, comparisons of the median percentage of positive staining 
among clinical classifications of all sarcoids and among BPV status groups (BPV1, BPV2 and 
BPV negative) were performed using Kruskal-Wallis Equality of Populations rank test and 
Dunn’s Multiple Comparison Test.  Significance was set at p<0.05. Analysis was performed with 
the aid of a statistical software package
f
. 
 
3.4 Results  
 Sarcoids of five clinical types were selected from a collection of equine sarcoid biopsies 
from horses in Western Canada.  Immunohistochemical staining results for Clc3, Survivin, Bcl-2 
are shown in Tables 3.1, 3.2, and 3.3.    All three of the antibodies produced 
immunohistochemical staining of control tissues consistent with the staining patterns described 
in other species.  
 
3.4.1 ClC3 
 Not surprisingly, ClC3 was expressed in control samples of thymus and lymph node 
(Figure 3.1C) and was not expressed in control skin samples (Figure 3.1A).  ClC3 staining was 
present in 60 of 76 sarcoid samples, including all types of sarcoids (Table 3.1).  Only small 
numbers of neoplastic cells stained positively in all types of sarcoids. When staining was present, 
cells had prominent cytoplasmic granular staining (Figure 3.1B).  The highest proportion of 
staining was in fibroblastic sarcoids where 15 of 15 sarcoids stained positively, with a median of 
1.2% of neoplastic fibroblasts in this type stained positively.  The lowest proportion of staining 
was present in occult sarcoids where eight of 15 samples had positive staining of any neoplastic 
fibroblasts and a median of 0.40% of cells stained positively.  These two medians are 
significantly different (p<0.05).  Complete results are summarized in Table 3.1.   
 
3.4.2 Bcl-2 
 As expected, there was positive staining for Bcl-2 in the basal cells of the epithelium of 
control and sarcoid samples (Figure 3.2A), cells in lymph node (Figure 3.2C), and in pancreas.  
Fibroblasts in control skin samples did not stain with Bcl-2 antibody (Figure 2A).  Weak diffuse 
cytoplasmic staining for Bcl-2 was present only in small numbers of sarcoid samples (19 of 66 
sarcoids) and a small number of neoplastic cells in these samples, (Table 3.2, Figure 3.2B).  
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Again, the highest proportion of staining in neoplastic cells was within fibroblastic sarcoids, but 
the magnitude of difference amoung the clinical types of sarcoids was not statistically 
significant. 
 
3.4.3 Survivin 
 Control tissues stained as expected in that, Survivin was detected in fetal thymus (Figure 
3.3C) and gastric epithelium and no staining was present in control adult equine dermal 
fibroblasts (Figure 3.3A). All types of sarcoids had neoplastic cells that stained for Survivin and 
59 of the 76 sarcoids stained positively (Table 3.3).  Higher proportions of nodular and 
fibroblastic sarcoids stained positively (14 of 15 samples and 13 of 15 samples respectively), as 
compared to occult sarcoids where seven of 15 sarcoids had positive staining.  Median 
percentage of positively staining cells in the area of greatest staining intensity varied from 0% in 
occult sarcoids to 6.6% in fibroblastic sarcoids which is statistically significant (p<0.05).  
Positive staining was nuclear and granular in character (Figure 3.3B).  
 
3.4.4 Immunohistochemical staining and BPV type 
    No statistically significant difference was found in staining characteristics amoung any 
of the antibodies (Clc3, Survivin, Bcl-2) and BPV type ( BPV1, BPV2 or BPV negative) in the 
76 sarcoids (data not shown).   
 
3.5 Discussion 
 Apoptosis, the programmed death and removal of cells, is a common occurrence in 
neoplastic processes as a result of irreparable DNA damage. However, evasion of apoptosis by 
neoplastic cells is also an adaptation seen in many different tumours and allows for neoplastic 
cell survival and replication.  As far as can be determined, examination of equine sarcoids to 
detect evasion of apoptosis by neoplastic cells has not been previously reported.  In this study, 
equine sarcoids of different clinical types were examined immunohistochemically to determine 
their expression of three markers: one associated with apoptosis (ClC3) and two associated with 
the evasion of apoptosis (Bcl-2 and Survivin).   
No previous reports describing the use of these markers in FFPE equine tissues of any 
sort have been published.  All of these proteins are highly conserved among species and have 
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been studied in other domestic animal species.  Based on staining characteristics reported in 
other species, numerous normal FFPE equine tissues, including adult haired skin, fetal tissues 
including thymus, stomach, pancreas and lymph node, were examined and found to exhibit the 
expected staining characteristics for these antibodies (Johnson and Howerth, 2004;Korsmeyer, 
1992;Madewell and others, 1999;Resendes and others, 2004), as shown in Figures 3.1, 3.2 and 
3.3.   
Immunohistochemistry has been previously used to help identify apoptotic cells in 
formalin-fixed tissue sections.  Two methods are commonly used, immunohistochemistry with 
antibodies to ClC3 and Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL).  ClC3 was chosen for use in this study as it has been reported to be more specific in 
the identification of apoptotic cells than is TUNEL (Duan and others, 2003;Gown and 
Willingham, 2002).  The number of apoptotic cells present in sarcoids in the current study was 
generally low (Table 3.1).  However, differences in positive staining of neoplastic fibroblasts 
were present between the types of sarcoids examined; all fibroblastic sarcoids had some positive 
staining neoplastic cells, while seven of 15 occult sarcoids had no positive staining whatsoever. 
A significantly higher proportion of neoplastic cells in fibroblastic sarcoids were positive for 
ClC3 than in occult sarcoids.  This may reflect a more unstable population of neoplastic cells in 
fibroblastic sarcoids, as compared to occult sarcoids.  By definition, fibroblastic sarcoids are 
more likely to be ulcerated and secondarily inflamed than occult sarcoids, (Knottenbelt, 2006) 
and, as ulceration and inflammation are positively associated with apoptosis (Myers and 
McGavin, 2007), the observed differences in apoptotic levels may be attributable to this.  
In the current study Bcl-2, a marker of decreased apoptosis, was present in a relatively 
few sarcoids (19 of 66 sarcoids) of any clinical type and a low percentage of neoplastic cells in 
these 19 sarcoids (Table 3.2). Having few neoplastic fibroblasts evading apoptosis, as evidenced 
by Bcl-2 staining, and few of these cells in apoptosis as demonstrated by Clc3 staining is not 
contradictory, as Bcl-2 is not normally expressed at all in the fibroblasts of adult skin, yet this 
lack of expression is not associated with increased levels of apoptosis (Hockenbery and others, 
1991;Pablos and others, 1997).  No significant difference in expression of Bcl-2 was present 
among the various types of sarcoids examined.  This would suggest that the expression of Bcl-2 
has a limited role in the development of the different clinical classifications of equine sarcoids. 
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Survivin is a member of a group of proteins, collectively known as inhibitor of apoptosis 
proteins, that are found in a wide variety of life forms from yeasts to vertebrates (Johnson and 
Howerth, 2004).  Survivin has a role in two important cell functions: regulation of normal cell 
division (Li and others, 1998) and evasion of apoptosis (Altieri and Marchisio, 1999).   
Normally, Survivin is not expressed in differentiated adult tissues (Ambrosini, Adida, and 
Altieri, 1997), but it is widely expressed in fetal tissues (Adida and others, 1998).  The 
expression of Survivin in many different neoplastic processes has been described and its 
expression is frequently associated with more clinically aggressive tumour types (Frost and 
others, 2002;Murakami and others, 2008;Rebhun and others, 2008;Takai and others, 2002;Yaqin, 
Runhua, and Fuxi, 2007).  
In the current study, expression of Survivin was commonly detected (59 of 76 samples) 
in the neoplastic fibroblasts of equine sarcoids (Table 3.3).  Positive staining for Survivin was 
present in most nodular (14 of 15 sarcoids) and fibroblastic sarcoids (13 of 15 sarcoids), but in 
only eight of 15 occult sarcoids.  The proportion of positively staining neoplastic cells varied 
among samples and significantly higher proportions were present in the areas of greatest staining 
intensity of fibroblastic and nodular type sarcoids than in occult type sarcoids (Table 3.3).  The 
occult type of sarcoid is the most clinically benign, while the fibroblastic type is the most 
clinically aggressive (Knottenbelt, 2005).  The increased likelihood of Survivin expression with 
increasing clinical aggressiveness has been described in other tumours caused by 
papillomaviruses, most notably in cervical cancers in women caused by HPV (Yaqin, Runhua, 
and Fuxi, 2007). Increased Survivin expression may represent an explanation for the increased 
clinical aggressiveness of fibroblastic sarcoids as compared to less aggressive types like occult 
sarcoids. 
  Expression of E6, an oncogene of papillomaviruses, in HPV infections has been 
positively correlated with Survivin expression (Borbely and others, 2006).  This correlation was 
shown to be related to effects of E6 on p53, an important tumour suppressor gene.  Specifically, 
in HPV, E6 causes degradation of p53 and removal of p53 is correlated to increased Survivin 
expression in these infected cells.  In contrast to HPV, BPV E6 does not cause degradation of 
p53 (Werness, Levine, and Howley, 1990), but instead has been shown to sequester p53 in an 
abnormal perinuclear location which may prevent its normal function (Martens and others, 
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2000;Nixon and others, 2005).  Whether the prevention of normal p53 functioning is the cause of 
the expression of Survivin in sarcoids seen in the current study is unknown.  
Expression of Survivin in sarcoids may have implications for the recurrence of sarcoids 
following treatment.  However, further research would be needed to determine this.  In addition, 
this expression may be useful for the development of new treatment modalities for equine 
sarcoids.  As Survivin is not normally expressed in adult tissues, it may represent a novel 
therapeutic target.  Several studies have been recently published using therapies targeted at 
Survivin expression in neoplastic cells as treatment methods (Chen and others, 2009;Lu and 
others, 2008;Wu and others, 2008).  Whether equine sarcoids could be treated in a similar 
manner is currently unknown.  
The BPV present in the sarcoid samples in this study had been previously typed as BPV 
types 1 or 2 using PCR and RFLP.  No difference in the expression of any of the three markers 
used in this study could be seen according to BPV type associated with these sarcoids. 
In summary, in this study immunohistochemistry was used to detect the presence of three 
markers associated with apoptosis or evasion of apoptosis (ClC3, Bcl-2 and Survivin) in different 
clinical types of equine sarcoids.  The use of these immunohistochemical markers on FFPE 
equine tissues has not been previously reported.  Levels of apoptosis as measured by 
immunoreactivity for ClC3 were significantly higher in fibroblastic sarcoids than in the less 
clinically aggressive occult sarcoids.  No differences in Bcl-2 expression were present among 
sarcoid types. Survivin was expressed in all types of sarcoids and in more clinically aggressive 
types of sarcoids the expression of Survivin was significantly higher.  This suggests that evasion 
of apoptosis is a clinically important factor in sarcoid development.  No differences in the 
expression of any of the three markers were present among sarcoids associated with different 
BPV types.  This study provides further insight into the pathogenesis of sarcoid progression and 
suggests that Survivin may be a useful therapeutic target for the development of new therapies 
for treatment of sarcoids. 
   
3.6 Sources and Manufacturers 
a
Benchmark staining platform, Ventana Medical Systems Inc., Tucson, AZ 
b
BMK iVIEW DAB Paraffin detection kits, Ventana Medical Systems Inc., Tucson, AZ 
c
Bcl2 Oncoprotein VP-B201, Vector Laboratories, Burlingame, CA 
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d
Cleaved Caspase-3 (Asp175) Antibody #9661, Cell Signaling Technologies, Danvers, MA 
e
Survivin Antibody NB500-201, Novus Biologicals LLC, Littleton, CO  
f
Prism 5 for Windows, Graphpad Software, La Jolla, CA 
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Table 3.1. Immunohistochemical expression of Cleaved Caspase-3 in 5 clinical types of equine 
sarcoids. 
 
 
  
Clinical 
Type of 
Sarcoid 
Proportion of 
Samples 
positive 
       % of Positively Staining Cells 
Minimum Median Maximum 
Occult 8/15 0.00 0.40 1.00 
Verrucose 13/16 0.00 0.70 2.20 
Nodular 13/15 0.00 0.60 2.00 
Fibroblastic 15/15 0.60 1.20 4.00 
Mixed 11/15 0.00 0.60 4.00 
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Table 3.2. Immunohistochemical expression of B-Cell Lymphoma 2 in 5 clinical types of equine 
sarcoids. 
 
 
 
Clinical 
Type of 
Sarcoid 
Proportion of 
Samples 
positive 
      % of Positively Staining Cells 
Minimum Median Maximum 
Occult 2/13 0.00 0.00 2.80 
Verrucose 3/14 0.00 0.00 5.00 
Nodular 4/14 0.00 0.00 2.80 
Fibroblastic 6/12 0.00 1.20 9.80 
Mixed 4/13 0.00 0.00 4.80 
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Table 3.3. Immunohistochemical expression of Survivin in five clinical types of equine sarcoids. 
 
 Clinical 
Type of 
Sarcoid 
Proportion of 
Samples 
positive 
      % of Positively Staining Cells 
Minimum Median Maximum 
Occult 7/15 0.00 0.00 10.20 
Verrucose 13/16 0.00 3.00 17.60 
Nodular 14/15 0.00 5.20 18.40 
Fibroblastic 13/15 0.00 6.60 21.40 
Mixed 12/15 0.00 4.00 15.00 
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Figure 3.1. Immunohistochemical staining using antibody to a marker of apoptosis in sections of 
normal and sarcoid bearing equine tissue. Antibody staining for Cleaved Caspase 3. 
 
 
A. Negative Control - Normal equine skin: note lack of staining of dermal fibroblasts. B. 
Fibroblastic sarcoid: note strong positive cytoplasmic staining of neoplastic fibroblasts. C - 
Positive control lymph node: note positive cytoplasmic staining.
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Figure 3. 2. Immunohistochemical staining using antibody to a marker of evasion of apoptosis 
in sections of normal and sarcoid bearing equine tissue. Antibody staining for B-Cell 
Lymphoma 2. 
 
 
A. Negative Control- Skin: note positive staining of basal epithelial cells and lack of staining of 
dermal fibroblasts. B. Fibroblastic sarcoid: note positive cytoplasmic staining of neoplastic 
fibroblasts. C. Positive control - Lymph Node: note positive cytoplasmic staining. 
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Figure 3.3. Immunohistochemical staining using antibody to a marker of evasion of apoptosis in 
sections of normal and sarcoid bearing equine tissue. Antibody staining for Survivin. 
   
 
A. Negative Control- Skin: note lack of staining of dermal fibroblasts. B. Fibroblastic sarcoid: 
note strong positive granular cytoplasmic staining of neoplastic fibroblasts. C. Positive control – 
Thymus: note positive cytoplasmic staining. 
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4. LOCALIZATION OF BOVINE PAPILLOMAVIRUS IN EQUINE SARCOIDS AND 
INFLAMMATORY SKIN CONDITIONS OF HORSES USING LASER 
MICRODISSECTION AND TWO FORMS OF DNA AMPLIFICATION 
 
 
 In addition to sarcoids, BPV has been found in non-sarcoid skin conditions.  How often 
this occurs and whether the location of BPV is different in sarcoids than in these other skin 
conditions is unclear.  To investigate this, PCR was used to detect BPV in sample paraffin 
histologic blocks of a variety of inflammatory skin conditions of horses and normal equine skin.  
Those samples in which BPV was detected were used for further study.  In addition to these, the 
BPV positive paraffin histologic blocks from sarcoids in the studies described in Chapter Two 
were used.  Using laser microdissection, all of the samples were divided into various tissue 
compartments and each of these compartments was then individually tested using PCR and a 
new amplification technique, LAMP, for the presence of BPV DNA.   BPV DNA was detected 
in nearly half of all non-sarcoid samples tested.  In sarcoids, BPV DNA was more likely to be 
found in morphologically neoplastic fibroblasts than in other tissues from the same histologic 
section.  BPV DNA was more often present in the epithelium of non-sarcoid samples than in the 
epithelium of sarcoid samples.  In non-sarcoid samples areas of inflammation were significantly 
more likely to contain BPV DNA than were non-inflamed areas.  
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4.1 Abstract 
 
Equine sarcoids are the most common skin tumour of horses.  Bovine papillomavirus (BPV) has 
been suggested as the causative agent of sarcoid formation.  Yet, several studies have shown that 
BPV is present in swabs or biopsies from non-sarcoid bearing equine skin.  The frequency of 
BPV detection in or on skin biopsies from non-sarcoid inflammatory conditions has never been 
examined, nor has the location of the BPV DNA in these samples been determined.  BPV DNA 
has recently been demonstrated in keratinocytes of a small number of equine sarcoids and its 
presence in these cells may depend on the clinical type of sarcoid examined.  In the current 
study, equine skin biopsies from a variety of different non-sarcoid skin conditions and 
histologically normal skin from horses with no reported history of sarcoids were examined by 
PCR for the presence of BPV DNA.  BPV DNA was found in all different types of skin 
conditions, as well as normal skin.  Overall, 41/86 skin biopsies from horses without sarcoids 
were found to contain BPV DNA.  Laser microdissection followed by DNA amplification by 
both PCR and isothermal loop mediated amplification was performed on these biopsies and 
upon, 70 BPV positive sarcoid biopsies in order to localize BPV DNA within these biopsies.  
Sarcoid samples were more likely to have BPV DNA in morphologically neoplastic fibroblasts 
than in other tissues on the same histologic slide (p=0.0005).  The location of BPV DNA was 
different between sarcoid and non-sarcoid groups.  Non-sarcoid skin biopsies were significantly 
more likely to have BPV DNA within intact or inflamed epidermis than sarcoids (p=0.016 and 
p=0.007, respectively).  Sarcoids were more likely to have BPV DNA in the non-inflamed 
dermis than non-sarcoid samples, but not significantly so.  In addition, areas of inflammation 
within the dermis and epidermis were more likely to contain BPV DNA than non-inflamed areas 
(p=0.008 and p=0.009, respectively).  BPV DNA was also found in the epidermis of all clinical 
types of equine sarcoids examined, but more frequently in occult sarcoids than in fibroblastic and 
nodular types (p=0.03 and p=0.01, respectively).  These results suggest that BPV is commonly 
found in equine skin. In non-sarcoid samples, BPV is more often located in the epidermis than in 
sarcoids.  Wherever it is located, it is more likely to be associated with inflammation suggesting 
that microscopic damage and inflammation within the skin may be a sufficient predisposing 
factor to the development of sarcoids.  
Key Words: equine sarcoid; Bovine papillomavirus; laser microdissection, LAMP
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4.2 Introduction 
 Bovine papillomavirus (BPV) has been associated with the development of the most 
common skin tumour of horses, the equine sarcoid (Chambers and others, 2003).  This 
association has been made based on the detection of BPV DNA in equine sarcoids and its 
absence in other equine skin tumours (Nasir and Campo, 2008).  Given this association, BPV has 
been suggested as the cause of equine sarcoids.  However, some studies have found BPV DNA 
in the skin of a small number of horses with non-sarcoid related inflammatory skin conditions, 
but the significance of this is unknown (Angelos and others, 1991;Chambers and others, 
2003;Yuan and others, 2007). 
 The frequency with which BPV can be found in non-sarcoid skin conditions has not been 
determined in a larger sample of equine tissues.  In addition, it is unclear where BPV is located 
histologically in these biopsies from non-sarcoid bearing horses.  If the same BPV can be 
commonly found in non-sarcoid skin conditions of horses and is present in the same histologic 
locations in these conditions as in equine sarcoids, the theory that BPV causes equine sarcoids 
may be called into question. 
 Previous studies have utilized polymerase chain reaction (PCR) to amplify the BPV DNA 
present in samples to allow for its identification, but this technique does not identify where 
within the sample BPV is located (Bloch, Breen, and Spradbrow, 1994;Carr and others, 
2001;Martens and others, 2001;Otten and others, 1993;Teifke, Hardt M., and Weiss, 1994).  
Studies have demonstrated the location of BPV in sarcoids using in situ hybridization (ISH) 
(Kidney and Berrocal, 2008;Teifke, Hardt M., and Weiss, 1994).  This technique allows for the 
visualization of BPV, but does not amplify the BPV to any significant degree when compared to 
PCR and is, therefore, a much less sensitive technique for identification of DNA when it is 
present in small quantities (Martens, De Moor, and Ducatelle, 2001).  Laser microdissection 
(LCM) allows for the very precise excision of a cell or cells from a sample of interest.  These 
excised cells become the template for DNA amplification allowing an accurate determination of 
where in a tissue sample the DNA of interest is located. 
Numerous techniques exist to amplify DNA.  PCR has frequently been used in the study 
of equine sarcoids.  More recently, another technique, isothermal loop mediated amplification 
(LAMP), has been developed (Notomi and others, 2000).  It has been purported to be as sensitive 
as PCR for the detection of DNA and is potentially more rapid and less expensive (Tomita and 
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others, 2008). The use of LAMP in equine tissue or in combination with laser microdissection 
has not, to the authors’ knowledge, been previously reported.  
Historically, BPV DNA had only been found within the neoplastic fibroblasts of equine 
sarcoids and not within the epidermis. However, a recent study examined a small number of 
sarcoids using LCM and found BPV DNA in the keratinocytes of the epidermis (Bogaert and 
others, 2010).  The presence of BPV DNA varied depending on the type of sarcoid examined.  
The authors’ suggested that BPV DNA location may change as sarcoids progress to different 
clinical types.  Only one clinical type of sarcoid was identified and examined in this 2010 study, 
so further research to see if this result is repeatable and applies to different clinical types of 
sarcoids is required. 
This study consisted of three parts. Part A was conducted to determine the frequency with 
which BPV DNA could be detected in non-sarcoid skin conditions of horses and whether it was 
the same type and has the same partial gene sequence as that found in sarcoids. Part B used BPV 
positive sarcoid biopsies and BPV positive non-sarcoid skin condition biopsies from part A and 
utilized LCM in combination with PCR and LAMP to determine if differences existed in the 
location of BPV in BPV positive sarcoids and non-sarcoid skin conditions of horses.  In addition, 
the viability of LAMP as a DNA amplification technique in formalin-fixed paraffin embedded 
(FFPE) equine tissue dissected by LCM was examined.  The information gleaned from part A 
and B, helped further clarify the role of BPV in the development of equine sarcoids.   In part C of 
this study, the location of BPV DNA in a variety of different clinical types of sarcoids was 
determined to discover if BPV location varies between types and between more and less 
clinically aggressive types. 
 
4.3 Materials and Methods 
4.3.1 Detection of BPV in non-sarcoid conditions of equine skin 
Surgical equine skin biopsies of non-neoplastic conditions diagnosed during the 12 year 
period between January 1, 1986, and December 31, 2007, inclusive, were identified by using 
computer-based record searches at the Department of Veterinary Pathology at the University of 
Saskatchewan and Prairie Diagnostic Services, Inc., (PDS) in Regina and Saskatoon, 
Saskatchewan.   From this series of collected records, samples of inflammatory skin conditions 
of a variety of different types were selected.  These conditions were chosen based on their 
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frequency of occurrence or clinical similarity to equine sarcoids (Table 4.1).  Normal skin 
samples were selected from horses with no reported history of sarcoids and which had 
morphologically and histologically normal skin biopsies taken as control samples in cases of 
non-sarcoid inflammatory skin conditions. In total, the 86 most recent cases were chosen (Table 
4.2). From these cases, the formalin-fixed paraffin embedded (FFPE) tissues were retrieved for 
PCR. The FFPE tissue blocks from these samples were utilized for PCR as previously described 
(Teifke, Hardt M., and Weiss, 1994).  Briefly, 100 µm thick sections were cut from the FFPE 
block using a microtome.  The microtome was cleaned using acetone between samples and blank 
paraffin blocks were cut every five samples for use as negative controls.  The single primer set 
that amplifies a 244 base pair (bp) sequence spanning portions of the E2 gene, the intergenic 
spacer region and a small portion of the E5 gene of BPV type 1 (BPV1), or a similarly located 
248 bp sequence of BPV type 2 (BPV2), was utilized (Table 4.3).  To confirm that amplified 
product was BPV, the 17 most strongly positive PCR samples were nucleotide sequenced. 
 
4.3.2 Laser microdissection, PCR and LAMP amplification of BPV positive equine sarcoids 
and non-sarcoid equine skin conditions 
 The 41 tissue biopsies from Part A that were positive by PCR for BPV DNA and all BPV 
positive equine sarcoid biopsies with sufficient remaining tissue (70 samples) collected for a 
previous study (Wobeser and others, 2010) were used for this study.  Sections 5 µm thick were 
cut from the FFPE blocks, affixed to specialized membrane covered glass slides designed for use 
with laser microdissection (MembraneSlide 1.0 PEN; Carl Zeiss Canada Ltd., Toronto, Canada), 
and stained with hematoxylin and eosin.  No coverslips were affixed. 
 Using a laser microscope dissection system (PALM MicroBeam; Carl Zeiss Canada Ltd., 
Toronto, Canada) each slide was examined under 200x magnification by a Diplomate of the 
American College of Veterinary Pathologists (BKW).  When present on the slide, portions 
consisting of various tissue compartments (Table 4.4) were excised with the laser and catapulted 
into individual 500 µL microcapillary tubes (AdhesiveCap 500; Carl Zeiss Canada Ltd., Toronto, 
Canada).  A minimum of 5 x 10
6
 µm
3
 of tissue was collected into each tube.  DNA from the 
tissue within these tubes was extracted as previously described (Teifke, Hardt M., and Weiss, 
1994).  DNA extracted and precipitated was resuspended in 10 µL of Tris EDTA buffer. 
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 To confirm that amplifiable DNA was present in each sample following DNA extraction, 
PCR using primers that amplify a 247 bp sequence of the equine actin gene was utilized (Table 
4.3).  The reaction mixture was as follows : 5 mM KCl and 1 mM Tris HCl, 3 mM MgCl2, 200 
µM of each dNTP, 1 µM of each primer, 1.25 units of Taq DNA polymerase, 3 µL of template 
DNA and sufficient water for a final reaction volume of 50 µL.  Amplification conditions were 
94º C for 3 minutes, followed by 40 cycles of 94º C for 30 seconds, 59º C for 60 seconds, 72º C 
for 60 seconds followed by a final extension period of 72º C for 10 minutes. Confirmation that 
the PCR product was equine actin was conducted by nucleotide sequencing. 
 After confirmation that amplifiable DNA was present in the sample, PCR for BPV DNA 
using the same method used in the part A was performed on each sample with the exception that 
the number of cycles was increased from 40 to 45 to account for the smaller sample volume 
acquired by laser microdissection.  In addition to PCR, LAMP was also performed on each 
sample.  Positive and negative controls for both PCR and LAMP included sequenced, BPV-
positive bovine papilloma, tissue-free sections of slide membrane to act as negative controls and 
standard no template controls.  The LAMP primer set used amplifies a portion of the same 
sequence of the E2 and E5 genes used for PCR (Table 4.3).  Using Primer Explorer V4 (Eiken 
Chemical Co LTD, Japan, http://primerexplorer.jp/e/) and the 244 base pair sequence of E2 and 
E5 that the BPV PCR amplifies, four sets of primers were designed.  All were optimized using a 
cloned BPV E2 and E5 amplicon originally derived from an equine sarcoid.  The primer set used 
in this experiment was chosen from the four designed sets based on consistent and strong 
amplification.  LAMP reaction solution was composed of 2 mM Tris-HCl, 1 mM (NH4)2SO4, 
1 mM KCl, 0.2 mM MgSO4, 0.1% Triton X-100, pH 8.8, 2 mM MgCl2, 200 µM of each dNTP, 
1.6 µM of FIP and BIP primers, 0.2 µM of F3 and B3 primers, 32 units of Bst DNA polymerase 
large fragment, 3 µL of template DNA and sufficient water for a final reaction volume of 50 µL.  
The reaction was heated at 65º C for 60 minutes.  Following isothermal amplification, positive 
products were identified using electrophoresis on a 2% agarose gel stained with ethidium 
bromide and visualized under UV light. 
 
4.3.3 Presence of BPV DNA in the keratinocytes of different clinical types of sarcoids 
 The clinical types of sarcoids used in Part B of this study had been previously identified 
(Wobeser and others, 2010).  Sarcoids from four different clinical types (occult, verrucous, 
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nodular and fibroblastic) were considered in this portion of the study.  A fifth clinical type of 
sarcoid (mixed) used in part B was not utilized for this portion of the study as mixed sarcoids 
exhibit features from one or more of the other four sarcoid types and are, therefore, not a 
homogenous clinical type.  BPV DNA positivity in the epidermal compartments from each of 
these four different clinical types of sarcoids was compared.  
  
4.3.4 Statistical analysis 
 Comparisons of the recovery rates of BPV DNA between sarcoid and non-sarcoid groups 
were made using Fisher’s exact tests.  Comparisons of recovery rates of BPV DNA between 
matched samples of sarcoid or non-sarcoid groups were made using McNemar’s test.  Relative 
risk of BPV positivity in the epidermis amongst different clinical types of sarcoids was made 
based on comparison with the clinical types with the lowest risk of BPV positivity.  The 
comparison of agreement between LAMP and PCR was made using an unweighted Kappa test.  
P values of <0.05 were considered significant. 
 
4.4 Results 
4.4.1 Presence of BPV in non-sarcoid conditions of equine skin 
 A total of 86 cases of non-sarcoid, non-neoplastic skin conditions including histologically 
normal skin from horses with no history of sarcoids were examined.  Results are summarized in 
Table 4.2.  BPV DNA positive samples were found in all conditions examined including normal 
skin.  Overall, 41 of 86 (47.6%) samples were positive for BPV DNA.  This is significantly 
lower than the proportion of sarcoid samples found to contain BPV DNA by the same 
methodology (p=0.0001).  No significant difference in the proportion of positive samples was 
present amoung any skin conditions or normal skin.  All negative controls including blank 
paraffin blocks cut during the microtome cutting procedure were negative.  
 A total of 17 of the 41 positive samples were sequenced. These sequences were compared 
to sequences in GenBank using the Basic Local Alignment Search Tool (BLAST) (Altschul and 
others, 1997).  Of the 17 samples sequenced, eight were identical to BPV1 obtained from equine 
sarcoids in Western Canada (GenBank accession number FJ895875) and nine of the 17 showed 
100% identity to BPV2 found in sarcoids in Western Canada (GenBank accession number 
FJ895874).  
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4.4.2 Laser microdissection, PCR and LAMP amplification of BPV positive equine sarcoids 
and non-sarcoid equine skin conditions 
 Sufficient material remained within the BPV DNA positive FFPE blocks to perform 
LCM, PCR and LAMP in 70 equine sarcoid samples and 37 non-sarcoid samples.  These 107 
samples were cut into a total of 334 tissue compartments (Table 4.4) for examination for BPV by 
DNA amplification.  
 PCR for equine actin was positive in all 334 tissue compartments showing that 
amplifiable DNA was present in all samples.  BPV was detected by PCR, LAMP, or both in 157 
of these compartments (47%).  Results are summarized in Table 4.5 and examples of 
corresponding PCR and LAMP gels are given in Figure 4.1.  PCR detected BPV DNA in more 
samples than did LAMP, detecting BPV DNA in 155 compartments, including 19 not detected 
by LAMP.  LAMP detected BPV DNA in 138 compartments including two not detected by PCR.  
Overall, results from PCR and LAMP agreed on 313 of 334 samples (93.7%).  This corresponds 
to an unweighted Kappa score of 0.87 (95% confidence interval 0.76-0.98), which is considered 
“almost perfect” agreement (Landis and Koch, 1977). Given this, tissue compartments from 
samples that were positive by either PCR or LAMP were considered positive for BPV DNA for 
the other parts of this study. 
 BPV DNA was found in 47% of tissue compartments in both sarcoid and non-sarcoid 
samples (Table 4.6).  Not all tissue compartments were present in any given sample.  For 
example, in normal skin, areas of inflamed epidermis or dermis do not exist.  Similarly, some 
samples of sarcoid no longer contained areas of morphologically neoplastic fibroblasts.  These 
areas were likely contained within sections of the FFPE block that were consumed during other 
testing.  In sarcoid samples, BPV DNA was most commonly detected within areas of 
morphologically neoplastic fibroblasts in the dermis.  BPV DNA was detected within 57 of the 
65 samples where this tissue compartment existed. Other areas of the superficial and deep dermis 
that were morphologically normal also contained BPV DNA (4/14 and 10/21, respectively, Table 
4.7).  Overall, in sarcoid samples, BPV DNA was significantly more likely to be recovered from 
morphologically neoplastic fibroblasts than from other tissues on the same histologic slides 
(p=0.0005, Table 4.8). 
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      Non-sarcoid samples were more likely to have BPV DNA in intact or inflamed epithelium 
than were sarcoid samples (p=0.016 and p=0.007 respectively, Table 4.7).  Sarcoid samples were 
more likely to have BPV DNA in non-inflamed dermis than non-sarcoid samples, but the 
differences were not significant.  Non-sarcoid samples were more likely to contain BPV in 
inflamed dermis and epidermis as compared to normal dermis and epidermis (p=0.008 and 
p=0.009, respectively, Table 4.8).   
 
4.4.3 Presence of BPV DNA within the epidermis of different clinical types of sarcoids 
 A total of 49 sarcoids of four clinical types contained sufficient epidermis for analysis.  
When these 49 sarcoids were subdivided based on clinical type into occult, verrucous, nodular, 
and fibroblastic, BPV DNA was present within the epidermis of all types (Table 4.9).  There was 
a significantly higher risk of BPV DNA being present in the epidermis of occult sarcoids 
compared to fibroblastic or nodular sarcoids.  There were no significant differences between the 
detection rate of BPV between verrucous sarcoids and occult ones.. 
 
4.5 Discussion 
 Equine sarcoids are the most common skin tumour of horses (Scott D.W. and Miller 
W.H., 2003;Valentine, 2006).  Their appearance in horses has been described for centuries.  
Currently, the development of sarcoids is believed to be associated with infection by BPV (Nasir 
and Campo, 2008).  This association has been made based upon the presence of BPV DNA in 
sarcoid lesions and its absence in other equine skin lesions.  The association of BPV with equine 
sarcoids is unlike other papillomaviral diseases for several reasons. First, other papillomaviruses 
are typically species specific and do not cause disease outside of their host species (Nasir and 
Campo, 2008).  Second, unlike other papillomaviral diseases, papillomavirus has not been 
isolated from sarcoids.  Third, using electron microscopy, viral particles have not been visualized 
in equine sarcoids. Finally, atypical of other papillomaviral diseases, attempts to recreate the 
disease by inoculation of BPV into the skin of horses have been unsuccessful (Olson and Cook, 
1951;Ragland and Spencer, 1969;Voss, 1969).  The causal association between the presence of 
BPV and the development of sarcoids is strengthened by the presence of BPV DNA in sarcoids 
and a lack of BPV DNA in other skin conditions of horses notably other skin tumours of horses.  
However, several studies have found BPV on the skin of normal horses (Bogaert and others, 
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2005;Bogaert and others, 2008) and one small study found BPV in all four cases of inflammatory 
skin conditions of horses that the researchers examined (Yuan and others, 2007).  If BPV is 
commonly found in non-sarcoid skin lesions the association between BPV infection and sarcoid 
development is weakened.  The purpose of this study was to examine a larger group of non-
sarcoid skin conditions of horses for the presence of BPV DNA and, if present, to determine if 
the distribution of BPV DNA in the skin is different in these non-sarcoid lesions than in sarcoids. 
 A total of 86 skin biopsies including a variety of non-sarcoid skin lesions and 
morphologically normal equine skin from horses with no reported history of sarcoids were 
examined using PCR on the FFPE tissues to determine if BPV DNA was present in these 
samples.  Nine categories of non-sarcoid equine skin samples were chosen based on the 
frequency of diagnosis over a ten year period at PDS and their similar clinical appearance to 
sarcoids (Table 4.1). 
BPV DNA was present in all categories of skin lesions examined, as well as normal skin 
(Table 4.2).  The overall prevalence varied from a low of 4/17 cases in eosinophilic granulomas 
to a high of 4/5 cases in photoactivated dermatitis.  The overall rate of 41/86 BPV DNA positive 
cases was surprisingly high.  In a study by the current authors examining the epidemiology of 
equine sarcoids in Western Canada, identical methods to determine the presence of BPV DNA in 
sarcoid biopsies was used (Wobeser and others, 2010).  In that study, 74/96 sarcoid samples were 
positive for BPV DNA.  While the recovery rate of BPV DNA in the current study was lower 
than that found in sarcoids (p=0.0001), BPV DNA was found with considerable frequency. 
Two types of BPV are commonly associated with equine sarcoids, BPV1 and BPV2.  
Sequencing of the BPV recovered from these non-sarcoid skin samples confirmed that one or the 
other of these types of BPV was present in the samples described here and that their partial gene 
sequences were identical to those found in equine sarcoids from the same geographic region. A 
previous study on the presence of BPV DNA in sarcoids and the skin of non-sarcoid bearing 
horses found that the proportion with BPV2 positivity was higher in non-sarcoid bearing horses 
than in sarcoid bearing horses suggesting that BPV2 may be a more easily cleared infection than 
BPV1 (Bogaert and others, 2008).  However, in the current study BPV1 and BPV2 DNA were 
recovered in roughly equal proportions in non-sarcoid bearing horses. This result was the 
opposite of that found in the 2008 study and the level of BPV1 recovery was actually higher than 
61 
 
the recovery rate from sarcoid bearing horses in Western Canada.  This suggests that there may 
be no difference in the duration of infection between BPV1 and BPV2. 
If the belief that BPV causes equine sarcoids is largely based on the presence of BPV 
DNA in sarcoids and absence from other equine skin samples, the fact that identical BPV DNA 
can be recovered from over 40% of other skin conditions in horses is problematic.  Direct 
visualization of the presence of BPV DNA in sarcoids in the past has relied on in situ 
hybridization.  While specific, this methodology does not have the required sensitivity to detect 
the small amount of BPV DNA in some components of tissue biopsies (Martens, De Moor, and 
Ducatelle, 2001). 
To enhance the sensitivity of detection, researchers have used other sample collection 
methodologies in combination with PCR for DNA amplification.  These include skin swabbing 
and scraping techniques to determine the presence of BPV on the surface of sarcoid bearing and 
non-sarcoid bearing horses.  In one such study, BPV DNA was detected in most of the sarcoid 
samples, but none of the non-sarcoid control samples (Martens, De Moor, and Ducatelle, 2001) 
which is in contrast to the frequency with which some studies, including the current one, were 
able to find BPV DNA in non-sarcoid equine skin samples (Bogaert and others, 2005).  In this 
2005 study, BPV DNA was detected on the skin surface of both non-sarcoid and sarcoid bearing 
horses. Perhaps, it is not simply the presence of BPV DNA alone that is important in sarcoid 
development; but also its location within the skin. 
 In one previous study the use of swabbing, cleaning and biopsying equine sarcoids, 
followed by PCR on the collected samples, was attempted to determine where within the lesion 
BPV was located (Bogaert and others, 2008).  The results were somewhat difficult to interpret as 
the methodology lacks the ability to precisely determine what is being sampled.  For example, in 
one horse BPV DNA was not present on a swab of the uncleaned skin surface, but was present 
after cleaning the skin surface.  To avoid this problem LCM was used in the current study.  The 
advantages of LCM are the ability to precisely choose specific areas or individual cells from a 
histologic slide of a lesion, and the ability to excise and capture these target areas without 
contamination from surrounding areas.  The PALM laser microdissection scope uses a UV laser 
to excise the cells of interest and then uses a diffuse blast of laser light to propel the excised cells 
into a collection chamber so that DNA contamination from surrounding cells or instruments does 
62 
 
not occur. Very recently a study has used LCM on equine sarcoids following the same reasoning 
(Bogaert and others, 2010). 
 Using this methodology, in the current study it was found that there were significant 
differences in the anatomic location from which BPV can be recovered from non-sarcoid and 
sarcoid skin samples (Table 4.7).  Non-sarcoid skin samples were more likely to have BPV DNA 
on or in the epidermis, than were sarcoid samples.   
In addition, the presence of BPV DNA was significantly associated with the presence of 
inflammation.  BPV DNA was more likely to be found in inflamed epidermis or dermis than in 
non-inflamed areas on the same slide (Table 4.8).  Skin trauma has been suggested as an 
important mechanism to allow BPV access to the dermal fibroblasts and to provide an 
environment conducive to the proliferation of BPV transformed cells (Bogaert and others, 2008).  
The current results suggest that macroscopic trauma is not required and that inflammation alone 
may be sufficient to allow BPV access to the dermal fibroblasts.  This may explain sarcoid 
development in locations on horses with no previous history of injury at that site. In addition, 
inflamed areas may represent potential sites for transmission of BPV from one horse to another 
by either contact or potentially via fomites.  In support of this theory is a report that the same 
BPV DNA found within equine sarcoids could also be found in face flies (Musca autumnalis) in 
the horses’ surroundings (Kemp-Symond, 2000).  
 A 2008 study demonstrated the presence of BPV DNA in circulating peripheral blood 
mononuclear cells of sarcoid bearing horses (Brandt and others, 2008).  This suggested a 
possible alternate explanation for the presence of BPV DNA in inflamed areas.  Rather than the 
environment being the source of BPV DNA infection at these sites, circulating blood 
mononuclear cells within the horse are the source and are concentrated at these sites of 
inflammation.   However, although areas of inflammation were more likely to have BPV DNA 
within them, BPV DNA was also found in tissue compartments without inflammation.  So a 
strictly internal source of infection seems unlikely. 
 A third possible explanation for the frequent presence of BPV in inflamed areas of the 
skin is that BPV infection itself may be a contributing cause of the inflammation.  Epidermal 
changes associated with BPV infection have been described (Bogaert and others, 2010;Bogaert 
and others, 2008).  Whether these changes predispose horses to the development of other 
inflammatory skin conditions in these areas is unclear. It may be that most horses are able to 
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clear the inflammatory processes associated with these BPV infections, but others are unable to 
avert infection and progression to sarcoid development occurs. 
 Recently, BPV DNA has been recovered from keratinocytes within the epidermis of 
sarcoids (Bogaert and others, 2010). In that study, BPV DNA was amplified from keratinocytes 
in occult sarcoids but not from “advanced” sarcoids.  The clinical classification of the sarcoids 
described as “advanced” was not identified.  The current study demonstrated that BPV DNA 
could be found within the epidermis of all examined clinical types of sarcoids.  However, BPV 
DNA in the epidermis was significantly more likely to be identified in occult sarcoids than in 
fibroblastic or nodular ones (Table 4.9).  Presuming that fibroblastic and nodular sarcoids are 
types of the “advanced” sarcoids described in the other study, these current studies results would 
agree that occult sarcoids are more likely to contain BPV DNA in the epidermis than are 
fibroblastic or nodular ones.  This may represent a shift in the location of BPV DNA as sarcoids 
change from less to more clinically aggressive. 
 Two methods of DNA amplification were utilized in this study, PCR and LAMP.  PCR 
has been extensively used to detect BPV in sarcoids in FFPE tissue (Bloch, Breen, and 
Spradbrow, 1994;Brandt and others, 2008;Carr and others, 2001;Carr and others, 2001;Martens 
and others, 2001;Otten and others, 1993;Teifke, Hardt M., and Weiss, 1994;Wobeser and others, 
2010), while LAMP has not.  LAMP is a relatively new DNA amplification technique first 
reported in 2000 (Notomi and others, 2000).  Some studies have shown it to be more sensitive 
for detection of low copy numbers than PCR (Chen, Chu, and Lu, 2010).  While LAMP has been 
used in a number of applications its use in FFPE equine tissue or with laser microdissection has 
not been described.  In the current study, agreement, as measured by unweighted Kappa, between 
PCR and LAMP was almost perfect.  PCR was more sensitive than LAMP, detecting 19 positive 
samples that LAMP did not, while LAMP detected two positive samples that PCR did not.  This 
level of agreement suggests that LAMP is a viable DNA amplification technique for use with 
laser microdissection. 
 In summary, BPV DNA was present in over 40% of all samples of non-sarcoid equine 
skin biopsies tested.  It was found in a variety of inflammatory skin conditions as well as normal 
equine skin.  The distribution of BPV within the skin was different in these samples than in 
equine sarcoids, as it was more likely to be found on or in the epidermis.  BPV was more likely 
to be found in microscopically inflamed areas than in microscopically normal areas of non-
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sarcoid samples.  This inflammation may cause defects in the skin barrier which allows BPV 
access through the skin surface to the underlying dermis of the skin where it may contribute to 
equine sarcoid formation.  Alternately, the inflammation itself may be partially a result of BPV 
infection and the inability of some horses to resolve the inflammation in these areas may lead to 
sarcoid formation. These results may provide new insight into the pathogenesis of sarcoid 
formation and also imply that diagnostic techniques for equine sarcoids which rely upon 
detection of BPV DNA from skin swabs, scrapings or biopsies are unlikely to be adequately 
specific.  
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Table 4.1. Non-sarcoid equine skin condition categories assessed for the presence of Bovine 
papillomavirus, brief descriptions and rationale for their inclusion. 
 
Skin condition type Description and inclusion rationale 
Dermatophytosis Infection by dermatophytes leading to 
hyperkeratosis and alopecia; clinically similar 
to occult sarcoids (Knottenbelt, 2006) 
Eosinophilic dermatitis Common skin condition characterized by 
perivascular eosinophilic inflammation; BPV 
positive in another study (Yuan and others, 
2007) 
Eosinophilic granuloma Nodular dermal eosinophilic inflammation; 
clinically similar to nodular sarcoid; BPV 
positive in another study (Yuan and others, 
2007) 
Exuberant granulation tissue Ulcerative, dermatitis with proliferative 
granulation tissue, also known as “proud 
flesh”; clinically similar to neoplastic sarcoid 
(Knottenbelt, 2006) and BPV positive in 
another study (Yuan and others, 2007) 
Normal skin Selected from horses with no reported history 
of sarcoids which had morphologically and 
histologically normal biopsies of skin taken by 
clinicians as control samples in cases of non-
sarcoid inflammatory skin conditions 
Pemphigus foliaceous Most common auto-immune skin disease of 
horses, clinically similar to occult sarcoid 
(Knottenbelt, 2006) 
Photoactivated dermatitis Sunlight induced vasculopathy; relatively 
common lesion in horses (Scott D.W. and 
Miller W.H., 2003) 
Urticaria Clinically distinct variant of hypersensitivity 
characterized by dermal edema, serum 
exudation and alopecia; common skin lesion of 
horses (Scott D.W. and Miller W.H., 2003);  
Vasculitis Type III hypersensitivity induced vasculitis; 
pathogenetically distinct from the more 
common photoactivated dermatitis 
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Table 4.2. The number and percentage of biopsies that were polymerase chain reaction positive 
for Bovine papillomavirus DNA grouped by inflammatory skin condition type as well as normal 
skin. 
 
Skin Condition Type Number of cases Number of cases BPV 
positive (%) 
Photoactivated dermatitis 5 4 (80.0%) 
Eosinophilic dermatitis 5 3 (60.0%) 
Vasculitis 5 3 (60.0%) 
Dermatophytosis 9 5 (55.6%) 
Pemphigus foliaceous 9 5 (55.6%) 
Exuberant Granulation Tissue 14 7 (50.0%) 
Normal Skin 12 6 (50.0%) 
Urticaria 10 4 (40.0%) 
Eosinophilic Granuloma 17 4 (23.5% 
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Table 4.3. Polymerase chain reaction (PCR) and isothermal loop mediated amplification 
(LAMP) DNA amplification primers used in formalin fixed paraffin embedded equine sarcoid 
and non-sarcoid skin biopsies.  
 
Primer Name Nucleotide Sequence (5’-3’) 
PCR 
Actin 
 
               Forward CACACTGTGCCCATCTACGA 
               Reverse GCAGCTCGTAGCTCTTCTCC 
Bovine Papillomavirus  
               Forward CAAAGGCAAGACTTTCTGAAACAT 
               Reverse AGACCTGTACAGGAGCACTCAA 
LAMP  
Bovine Papillomavirus 
 
               F3 CAAAGGCAAGACTTTCTGAA 
               B3 CAAGAAAAAACAAGAGTAAGAACAG 
               FIP CAGAAGTCCAAGCTGGCTGTACATGTACCACTACCTCCT 
               BIP ATCACTGCCATTGCTTTTTCTTCGCAGCAACTAGTCCCAAG 
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Table 4.4.  Tissue compartment descriptions for use in laser microdissection for the detection of 
Bovine papillomavirus in sarcoid and non-sarcoid skin samples 
 
Name of tissue compartment Description of tissue compartment 
Intact epidermis Epidermis extending from the stratum basale to 
the stratum corneum  
Inflamed epidermis As per intact epidermis and including any of: 
increased inflammatory cell numbers, 
hemorrhagic or serum exudates, dysplasia, 
erosion 
Superficial dermis Dermis extending from the level of the 
dermal/epidermal junction to the level of 
adnexal structures of the skin 
Deep dermis Dermis extending deep to the level of adnexal 
structures of the skin   
Inflamed dermis As per either superficial or deep dermis and 
including any of: increased inflammatory cell 
numbers, granulation tissue, hemorrhage, 
reactive fibroblasts and hypertrophic 
endothelial cells 
Neoplastic dermis Superficial or deep dermis, inflamed or not, 
and composed largely of morphologically 
neoplastic fibroblasts 
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Table 4.5. Comparison of number of samples positive and negative for the presence of Bovine 
papillomavirus (BPV) DNA using 2 different amplification techniques, polymerase chain 
reaction (PCR) and isothermal loop mediated amplification (LAMP), in 334 laser microdissected 
tissue compartments of equine skin. 
 
  PCR detection of BPV DNA   LAMP Total 
  Number of 
samples BPV 
Positive  
Number of 
samples BPV 
Negative 
 
     
LAMP 
detection of 
BPV DNA 
Number of samples 
BPV Positive  
136 2           138 
Number of samples 
BPV Negative 
19 177           196 
     
 PCR Total 155 179           334 
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Table 4.6. Sarcoids and non-sarcoid equine skin samples dissected into tissue compartments 
using laser microdissection and examined for the presence of Bovine papillomavirus (BPV) 
DNA using polymerase chain reaction and isothermal loop mediated amplification 
 
Skin Condition Sample Type 
(number of samples) 
Name of Tissue 
compartment 
Number of 
times present 
Number of times BPV 
positive (%) 
Sarcoid (70) Inflamed Epidermis 57 22 (38.6) 
Intact Epidermis 52 6  (11.5) 
Superficial Dermis 14 4 (28.6) 
Deep Dermis 21 10 (47.6) 
Inflamed Dermis 4 1 (25.0) 
Neoplastic Dermis 65 57 (87.7) 
Exuberant Granulation Tissue 
(6) 
Inflamed Epidermis 6 6 (100) 
Intact Epidermis 3 2 (66.7) 
Superficial Dermis 2 1 (50.0) 
Deep Dermis 4 2 (50.0) 
Inflamed Dermis 6 6 (100.0) 
Neoplastic Dermis 0 0 
Dermatophytosis (5) Inflamed Epidermis 5 3 (60.0) 
Intact Epidermis 4 0 (0) 
Superficial Dermis 2 0 (0) 
Deep Dermis 0 0 
Inflamed Dermis 4 1 (25.0) 
Neoplastic Dermis 0 0 
Normal Skin (5) Inflamed Epidermis 0 0 
Intact Epidermis 5 4 (80.0) 
Superficial Dermis 5 1 (20.0) 
Deep Dermis 3 1 (33.3) 
Inflamed Dermis 0 0 
Neoplastic Dermis 0 0 
Eosinophilic Granuloma (4) Inflamed Epidermis 4 2 (50.0) 
Intact Epidermis 2 0 (0) 
Superficial Dermis 3 0 (0) 
Deep Dermis 0 0 
Inflamed Dermis 4 2 (50.0) 
Neoplastic Dermis 0 0 
Pemphigus foliaceous (4) Inflamed Epidermis 3 2 (66.7) 
Intact Epidermis 4 3 (75.0) 
Superficial Dermis 4 2 (50.0) 
Deep Dermis 3 1 (33.3) 
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 Inflamed Dermis 0 0 
 Neoplastic Dermis 0 0 
Urticaria (4) Inflamed Epidermis 4 3 (75.0) 
Intact Epidermis 4 2 (50.0) 
Superficial Dermis 0 0 
Deep Dermis 2 0 (0) 
Inflamed Dermis 4 2 (50.0) 
Neoplastic Dermis 0 0 
Hypersensitivity (3) Inflamed Epidermis 3 2 (66.7) 
Intact Epidermis 3 2 (66.7) 
Superficial Dermis 0 0 
Deep Dermis 3 1 (33.3) 
Inflamed Dermis 3 2 (66.7) 
Neoplastic Dermis 0 0 
Photoactivated Dermatitis (3) Inflamed Epidermis 3 1 (33.3) 
Intact Epidermis 3 0(0) 
Superficial Dermis 1 0(0) 
Deep Dermis 0 0 
Inflamed Dermis 2 1(50.0) 
Neoplastic Dermis 0 0 
Vasculitis (3) Inflamed Epidermis 2 2(100.0) 
Intact Epidermis 2 0(0) 
Superficial Dermis 3 0(0) 
Deep Dermis 0 0 
Inflamed Dermis 3 0(0) 
Neoplastic Dermis 0 0 
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Table 4.7. Number and percentage of sarcoid and non-sarcoid equine skin samples dissected into 
tissue compartments using laser microdissection and examined for the presence of Bovine 
papillomavirus (BPV) DNA using polymerase chain reaction and isothermal loop mediated 
amplification.   
 
Tissue 
Compartment 
Skin Sample 
classification 
Number of 
samples BPV 
DNA positive 
Number of 
samples BPV 
DNA negative 
% positive P value
a
  
Intact 
epidermis 
 
Sarcoid 6 46 12 0.016 
Non-sarcoid 9 16 36 
Inflamed 
epidermis 
 
Sarcoid 22 35 39 0.007 
Non-sarcoid 21 9 70 
Superficial 
dermis 
 
Sarcoid 4 10 29 0.689 
Non-sarcoid 4 16 20 
Deep dermis 
 
 
Sarcoid 10 11 48 0.501 
Non-sarcoid 5 10 33 
Inflamed 
dermis 
Sarcoid 1 3 25 0.598 
Non-sarcoid 14 12 54 
      
a 
P value refers to the difference between percentages of BPV positive non-sarcoid skin samples 
to the percentage of BPV positive sarcoid skin samples within the same tissue compartment type 
as measured by Fisher’s exact test 
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Table 4.8.  Comparison of BPV DNA detection rates from laser microdissected equine skin 
samples where both compared tissue compartments were present within the same histologic 
sample. 
Skin Sample 
Classification 
Compartment 
Type 
Number 
of 
matched 
samples 
Number 
of samples 
BPV DNA 
positive 
Number of 
samples 
BPV DNA 
negative
 
% 
positive
 
P value
a 
Sarcoid  Neoplastic 
dermis 
65 57 8 88 0.0005 
Non-
neoplastic 
Tissue 
43 22 66 
Non-sarcoid Inflamed 
Epithelium 
25 19 6 76 0.009 
Non-inflamed 
Epithelium 
9 16 36 
Non-sarcoid Inflamed 
Dermis 
26 14 12 54 0.0077 
Non-inflamed 
dermis 
5 21 19 
 
a
 P value refers to the association of presence of BPV DNA from matched equine skin samples 
within the compared compartment types as measured by McNemar’s test. 
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Table 4.9. Presence of Bovine papillomavirus (BPV) within the epidermis of laser 
microdissected equine sarcoids of different clinical types and the relative risk of BPV positivity 
based on comparison to BPV positivity in occult sarcoids. 
 
Clinical Type 
of Sarcoid  
Number of 
samples with 
epidermis 
present on 
slide 
Number 
with BPV 
DNA in the 
epidermis  
Risk of 
BPV 
presence 
Relative 
Risk of 
BPV 
presence 
P value 
Occult 11 7  0.64 5.8 Reference
 
Verrucous 14 5  0.36 3.2 0.23 
Nodular 15 2  0.13 1.2 0.01 
Fibroblastic 9 1  0.11 1.0 0.03 
a 
significantly higher relative risk of being BPV positive 
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Figure 4.1. Ethidium bromide stained agarose gels of PCR and LAMP amplified Bovine 
papillomavirus DNA from corresponding laser microdissected tissue samples of equine skin. 
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5. GENERAL DISCUSSION 
5.1 Introduction 
 This thesis represents a series of investigations into various aspects of equine sarcoid 
epidemiology and etiopathogenesis.  Although equine sarcoids are very common neoplasms of 
horses, relatively little is known about several characteristics of sarcoid occurrence in Western 
Canada.  In addition to basic epidemiologic features of affected horses, how the actual neoplasms 
grow or the role of Bovine papillomavirus (BPV) in sarcoid development is unknown.  The 
studies contained within this thesis were designed to investigate these characteristics.  
Summaries of these studies and their role in better understanding equine sarcoids along with 
possible future studies follow. 
5.2 Epidemiology of sarcoids in Western Canada 
5.2.1 Summary of Results 
 As was introduced in the first chapter, although equine sarcoids are a common neoplasm, 
relatively little is known about basic epidemiologic features, particularly these features in 
Western Canada.  In particular, breed, gender, age, and BPV type features associated with equine 
sarcoids, were examined at some depth in this thesis.  To investigate these, the largest collection 
of sarcoid records (802) in the reported literature was evaluated.  
  Various previous studies had suggested that some breeds of horses are more likely to 
develop sarcoids than are others (Angelos and others, 1988;Meredith and others, 
1986;Mohammed, Rebhun, and Antczak, 1992).  However, this thesis demonstrated that in 
Western Canada, Donkeys, but no specific breed of horse, were more likely to have sarcoids.  As 
discussed in Chapter 2, it is possible that this variance in reported breed predilection may be a 
result of different populations that were used to make these comparisons or may represent 
differences in the horses that inhabit these different geographic regions.   
  Horses with sarcoids were statistically younger than horses that had been biopsied for 
other reasons, which is not surprising as sarcoids are generally considered a disease of young 
horses.  Interestingly, the most aggressive clinical type of sarcoid, the fibroblastic type, was 
present in younger horses more often than were other clinical types of sarcoids.  This is curious 
because the general theory of sarcoid development is that sarcoids begin as a relatively benign 
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lesion of the occult or verrucose types and then these may transform into the more aggressive 
clinical types.  If this were the case, then the most aggressive clinical types would be more 
common in older horses than would the more benign clinical types.  A possible reason that this 
was not the case in this thesis may be that the sarcoid samples on which this thesis was based 
were derived from biopsy samples submitted by practicing veterinarians.  It may be that these 
veterinarians or the owners of the horses involved were more likely to biopsy these aggressive 
neoplasms early in the course of the disease, and were willing to wait a longer period of time 
before biopsying the more clinically benign lesions.   
 In this thesis, a large majority of the sarcoids contained BPV2 while a small minority 
contained BPV1.  Even though most studies done elsewhere in the world have found BPV1 to be 
the more common type found in sarcoids, the predominance of BPV2 was not entirely 
unexpected as one study found that BPV2 is more common in sarcoids than BPV1 in the 
Western United States (Carr and others, 2001).  Whether this variation in type prevalence is a 
result of differences in the virus or the horses present in different geographic regions is unknown, 
as no studies on the prevalence of the various types of BPV in different geographic regions have 
been done. 
 
5.2.2 Possible future studies based on this research 
 Sequences of the BPV DNA amplified from the sarcoids in this thesis were similar to 
sequences amplified from other sarcoids.  BPV1 and BPV2 are interesting viruses as the vast 
majority of other papillomaviruses are species specific, but these types of BPV seemingly are 
not.  This suggests a possible new research opportunity.  The typing and identification of BPV 
present in sarcoids is based on relatively short DNA sequences, commonly a section of the E2 
and E5 early genes, representing only a small portion of the total BPV genome.  It is possible 
that there are substantial differences in other portions of the genome of the BPV present in 
sarcoids.  The virus present in sarcoids may not be identical to the BPV1 and BPV2 viruses 
found in cattle, but may be novel viruses that simply share the previously sequenced portions.  
Subtypes of papillomaviruses, may only vary by 2% from one another based on sequence of a 
single gene, and the complete genome of very few non-human papillomaviruses are known (de 
Villiers and others, 2004).  It is expected that perhaps hundreds of currently unknown 
papillomaviruses exist (de Villiers and others, 2004).  To determine if BPV DNA recovered from 
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sarcoids is identical to BPV1 from cattle, amplification and sequencing of the whole genome of 
BPV from equine sarcoids would be needed.  This thesis used formalin-fixed paraffin embedded 
tissue (FFPE) which is very useful for retrospective studies, but cannot be used for total genome 
amplification as the fixation process prevents amplification of long DNA sequences.  As such, 
new studies attempting to sequence the entire genome would require the use of fresh sarcoid 
tissue in addition to other amplification and sequencing techniques, such as rolling circle 
amplification (Rector and others, 2005;Reimar and others, 2009).   
 
5.3 Immunohistochemistry of markers of apoptosis and evasion of apoptosis in equine 
sarcoids 
 This portion of the thesis was stimulated by the finding that the mitotic rate of neoplastic 
cells in sarcoids is not dramatically higher than in normal tissue (Borzacchiello and others, 
2008;Martens and others, 2000;Nixon and others, 2005).  If sarcoids do not grow by increased 
cell division then some other process such as increased cell longevity must result in tumour 
growth.  Evasion of apoptosis as a means of tumour growth as detected by immunohistochemical 
staining for Survivin and B-Cell Lymphoma 2 (Bcl-2) was, therefore, chosen to study in this 
thesis.  In addition to tumour growth, cervical neoplasms in women caused by papillomavirus 
have immunohistochemically detectable production of Survivin (Frost and others, 2002;Yaqin, 
Runhua, and Fuxi, 2007).  The production of this protein in these cervical tumours is associated 
with poorer prognosis and increased clinical aggressiveness.  In addition to providing 
information on how sarcoid tumours might grow, it was hoped that, based on 
immunohistochemical detection of production of Survivin and Bcl-2, prognostic information 
useful to veterinarians and horse owners might be provided.  One of the frustrations with the 
diagnosis of sarcoids is that beyond identifying the lesion as a sarcoid more specific information 
on the prognosis of that particular sarcoid cannot be given.  Sarcoids may never progress to 
clinical aggressiveness, may spontaneously regress or may, as is often the case, become more 
clinically aggressive.  If production of Survivin within a sarcoid could provide useful clinical 
information this would potentially be a useful diagnostic tool. 
 The results of this thesis support evasion of apoptosis as a method of sarcoid growth.  
Survivin was immunohistochemically detected in all types of sarcoids and was more often 
expressed in more clinically aggressive types of sarcoids than in less clinically aggressive types.  
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Statistically, this was significant, but for prognostic purposes the difference in Survivin protein 
production may not be large enough to provide accurate prognostic information on an individual 
sarcoid biopsy basis.  If expression of the Survivin gene is an important factor in transformation 
of sarcoids from less aggressive to more aggressive clinical types, it may be that 
immunohistochemistry is not a sufficiently sensitive test to detect small, but clinically important 
differences in Survivin expression. Measurement of mRNA activity of the Survivin gene may be 
a more sensitive technique.  While mRNA can be detected from FFPE blocks, it can be 
technically difficult to do so.  Again, as with whole genome amplification, fresh sarcoid tissue 
may be the ideal substrate for this type of research.  Using fresh tissue from different clinical 
types of sarcoids and quantitatively measuring mRNA levels of Survivin may allow for better 
differentiation of different clinical types of sarcoids and possibly provide better prognostic 
information.      
 
5. 4 Localization of BPV in equine sarcoids and non-sarcoid equine skin samples 
 The presence of BPV DNA in almost half of non-sarcoid skin samples was surprising.  
This level of detection suggests that any method of sarcoid diagnosis based on simple detection 
of BPV DNA is unlikely to be useful.  However, this thesis was able to show that although BPV 
DNA was present in these non-sarcoid samples, its location was different than in the sarcoid 
samples.  Laser microdissection and subsequent DNA amplification was an effective way of 
determining where the BPV DNA was located, but it was difficult and time consuming.  In situ 
methods, such as in situ PCR (IS-PCR) or in situ LAMP offer appealing alternative methods for 
localization of BPV DNA.  Other groups have had success demonstrating DNA with IS-PCR in 
other conditions.  Indeed, a considerable amount of time was spent during this PhD research 
trying to develop these techniques.  After some early success, the development of these was 
abandoned as consistent or predictable results could not be obtained.  The reasons for the failure 
of these tests in the hands of this researcher are not clear.  Troubleshooting of all parts of the 
processes was attempted, but without success. 
 The initial finding of the frequency of BPV DNA detection in non-sarcoid skin samples 
initially suggested that perhaps BPV was not a likely causative agent of sarcoid development.  
As was demonstrated in the later parts of the research the detection rate was significantly lower 
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in non-sarcoid skin conditions than in sarcoids and the location of BPV DNA within the sample 
differed between sarcoids and non-sarcoid skin samples.  These suggest that although simple 
detection of BPV DNA alone is insufficient to diagnose a sarcoid, there is ample evidence that 
BPV is a necessary factor in sarcoid development. 
 The presence of BPV DNA in normal dermal fibroblast in both sarcoid and non-sarcoid 
samples may provide an explanation of both the frequency of recurrence of sarcoids and the 
tendency of sarcoids to develop in multiple areas on the body.  If BPV DNA is present in these 
fibroblasts, when these fibroblasts are induced to more activated forms such as those present in 
areas of wound healing or inflammation then the BPV DNA within them may be stimulated to 
express oncogenic early genes and transform these morphologically normal cells into the 
neoplastic fibroblasts of a sarcoid.     
 It is interesting to speculate on why BPV DNA, which seems to be relatively ubiquitous 
on horses’ skin, causes development of sarcoids in some horses, but not in others.  This thesis 
suggests that the location of the BPV DNA may be one important factor in sarcoid development 
and that the presence of BPV DNA within the skin in non-sarcoid skin samples is associated with 
inflammation.  If there is inflammation present in these areas, why doesn’t the horse’s immune 
system react to and remove the BPV DNA before sarcoids are formed?  Tempting hints as to 
why this may occur can be found in earlier research which reported that sarcoids are found more 
frequently in horses with some equine leukocyte antigen (ELA) types (Brostrom, H. et al., 1988; 
Brostrom, H., 1995; Gerber, H. et al., 1988; Lazary, S. et al., 1985; Meredith, D. et al., 1986).  
As ELAs are associated with the immune response, it may be that horses with these ELA types 
have impaired clearance of BPV.  If this were to be the case then rather than BPV being 
efficiently removed, it may persist and lead to sarcoid development.  Research into this could 
provide valuable insight into the pathogenesis of sarcoid development.  In addition, if an 
impaired immune response is important in the development of sarcoids this may have 
implications for treatment or prevention modalities that rely on the immune system such as 
vaccination. 
  
5.5 Final discussion 
 This thesis has provided valuable insight into sarcoid development and answered several 
questions about the role of BPV in sarcoids.  However, like all research, by providing answers to 
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some questions it raises several new questions and new possible avenues of research.  As 
sarcoids remain the most common equine neoplasm and their clinical behavior remains 
frustratingly difficult to predict considerable research remains to be performed.   
  
82 
 
6. REFERENCES 
 
1. Adida, C., Crotty, P. L., McGrath, J., Berrebi, D., Diebold, J., and Altieri, D. C., 1998,   
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human 
and mouse differentiation: American Journal of Pathology, v. 152, p. 43-49. 
2. Altieri, D. C. and Marchisio, P. C., 1999, Survivin apoptosis: an interloper between cell death 
and cell proliferation in cancer: Laboratory Investigation, v. 79, p. 1327-1333. 
3. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, 
D. J., 1997, Gapped BLAST and PSI-BLAST: a new generation of protein database search 
programs: Nucleic Acids Research, v. 25, p. 3389-3402. 
4. Ambrosini, G., Adida, C., and Altieri, D. C., 1997, A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma: Nature Medicine, v. 3, p. 917-921. 
5. Angelos, J., Oppenheim, Y., Rebhun, W., Mohammed, H., and Antczak, D. F., 1988, 
Evaluation of breed as a risk factor for sarcoid and uveitis in horses: Animal Genetics, v. 19, p. 
417-425. 
6. Angelos, J. A., Marti, E., Lazary, S., and Carmichael, L. E., 1991, Characterization of BPV-
like DNA in equine sarcoids: Archives of Virology, v. 119, p. 95-109. 
7. Anjos, B. L., Silva, M. S., Diefenbach, A., Brito, M. d. F., Seppa, G. S., and Brum, M. C. S., 
2010, Equine sarcoid associated with bovine papillomavirus BR-UEL-4: Ciencia Rural, v. 40, p. 
1456-1459. 
8. Ashrafi, G. H., Piuko, K., Burden, F., Yuan, Z., Gault, E. A., Muller, M., Trawford, A., Reid, 
S. W. J., Nasir, L., and Campo, M. S., 2008, Vaccination of sarcoid-bearing donkeys with 
chimeric virus-like particles of bovine papillomavirus type 1: Journal of General Virology, v. 89, 
p. 148-157. 
9. Ashrafi, G. H., Tsirimonaki, E., Marchetti, B., O'Brien, P. M., Sibbet, G. J., Andrew, L., and 
Campo, M. S., 2002, Down-regulation of MHC class I by Bovine papillomavirus E5 
oncoproteins: Oncogene, v. 21, p. 248-259. 
10. Bloch, N., Breen, M., and Spradbrow, P. B., 1994, Genomic sequences of Bovine 
papillomaviruses in formalin-fixed sarcoids from Australian horses revealed by polymerase 
chain reaction: Veterinary Microbiology, v. 41, p. 163-172. 
83 
 
11. Bloch, N., Breen, M., and Spradbrow, P. B., 1994, Genomic sequences of bovine 
papillomaviruses in formalin-fixed sarcoids from Australian horses revealed by polymerase 
chain-reaction: Veterinary Microbiology, v. 41, p. 163-172. 
12. Bogaert, L., Martens, A., De, B. C., and Gasthuys, F., 2005, Detection of bovine 
papillomavirus DNA on the normal skin and in the habitual surroundings of horses with and 
without equine sarcoids: Research in Veterinary Science, v. 79, p. 253-258. 
13. Bogaert, L., Martens, A., Depoorter, P., and Gasthuys, F., 2008, Equine sarcoids - part 1: 
clinical presentation and epidemiology: Vlaams Diergeneeskundig Tijdschrift, v. 77, p. 2-9. 
14. Bogaert, L., Martens, A., Depoorter, P., and Gasthuys, F., 2008, Equine sarcoids - Part 2: 
current treatment modalities: Vlaams Diergeneeskundig Tijdschrift, v. 77, p. 62-67. 
15. Bogaert, L., Martens, A., Kast, W. M., Van Marck, E., and De Cock, H., 2010, Bovine 
papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors. Veterinary 
Microbiology v. 146, p. 269-275.  
16. Bogaert, L., Martens, A., Van, P. M., Ducatelle, R., De, C. H., Dewulf, J., De, B. C., 
Peelman, L., and Gasthuys, F., 2008, High prevalence of bovine papillomaviral DNA in the 
normal skin of equine sarcoid-affected and healthy horses: Veterinary Microbiology, v. 129, p. 
58-68. 
17. Bogaert, L., Van, P. M., De, B. C., Dewulf, J., Peelman, L., Ducatelle, R., Gasthuys, F., and 
Martens, A., 2007, Bovine papillomavirus load and mRNA expression, cell proliferation and p53 
expression in four clinical types of equine sarcoid: Journal of General Virology, v. 88, p. 2155-
2161. 
18. Borbely, A. A., Murvai, M., Konya, J., Beck, Z., Gergely, L., Li, F., and Veress, G., 2006, 
Effects of human papillomavirus type 16 oncoproteins on survivin gene expression: Journal of 
General Virology, v. 87, p. 287-294. 
19. Borzacchiello, G., Russo, V., Della Salda, L., Roperto, S., and Roperto, F., 2008, Expression 
of platelet-derived growth factor-beta receptor and Bovine papillomavirus E5 and E7 
oncoproteins in equine sarcoid: Journal of Comparative Pathology, v. 139, p. 231-237. 
20. Branca, M., Giorgi, C., Santini, D., Di, B. L., Ciotti, M., Costa, S., Benedetto, A., Casolati, E. 
A., Favalli, C., Paba, P., Di, B. P., Mariani, L., Syrjanen, S., Bonifacio, D., Accardi, L., 
Zanconati, F., and Syrjanen, K., 2005, Survivin as a marker of cervical intraepithelial neoplasia 
84 
 
and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical 
cancer: American Journal of Clinical Pathology, v. 124, p. 113-121. 
21. Brandt, S., Haralambus, R., Shafti-Keramat, S., Steinbom, R., Stanek, C., and Kirnbauer, R., 
2008, A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid 
protein: Virology, v. 375, p. 433-441. 
22. Brostrom, H., 1995, Equine sarcoids. A clinical and epidemiological study in relation to 
equine leucocyte antigens (ELA): Acta Veterinaria Scandinavica, v. 36, p. 223-236. 
23. Brostrom, H., Fahlbrink, E., Dubath, M. L., and Lazary, S., 1988, Association between 
equine leucocyte antigens (ELA) and equine sarcoid tumors in the population of Swedish 
Halfbreds and some of their families: Veterinary Immunology Immunopathology, v. 19, p. 215-
223. 
24. Carr, E. A., Theon, A. P., Madewell, B. R., Griffey, S. M., and Hitchcock, M. E., 2001, 
Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with 
and without sarcoids in the western United States: American Journal of Veterinary Research, v. 
62, p. 741-744. 
25. Carr, E. A., Theon, A. P., Madewell, B. R., Hitchcock, M. E., Schlegel, R., and Schiller, J. 
T., 2001, Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained 
from horses: American Journal of Veterinary Research, v. 62, p. 1212-1217. 
26. Chambers, G., Ellsmore, V. A., O'Brien, P. M., Reid, S. W., Love, S., Campo, M. S., and 
Nasir, L., 2003, Association of bovine papillomavirus with the equine sarcoid: Journal of 
General Virology, v. 84, p. 1055-1062. 
27. Chambers, G., Ellsmore, V. A., O'Brien, P. M., Reid, S. W. J., Love, S., Campo, M. S., and 
Nasir, L., 2003, Sequence variants of bovine papillomavirus E5 detected in equine sarcoids: 
Virus Research, v. 96, p. 141-145. 
28. Cheevers, W. P., Fatemi-Nainie, S., and Anderson, L. W., 1986, Spontaneous expression of 
an endogenous retrovirus by the equine sarcoid-derived MC-1 cell line: American Journal of 
Veterinary Research, v. 47, p. 50-52. 
29. Cheevers, W. P., Roberson, S. M., Brassfield, A. L., Davis, W. C., and Crawford, T. B., 
1982, Isolation of a retrovirus from cultured equine sarcoid tumor cells: American Journal of 
Veterinary Research, v. 43, p. 804-806. 
85 
 
30. Chen, H. T., Chu, Y. F., and Lu, Z. X. Loop-mediated isothermal amplification for the rapid 
detection of Haemophilus parasuis. FEMS Immunology Medicine Microbiology , no. 2010.  
Blackwell Publishing Ltd. In Press 
31. Chen, Z. Y., Liang, K., Xie, M. X., Wang, X. F., Lu, Q., and Zhang, J., 2009, Induced 
apoptosis with ultrasound-mediated microbubble destruction and shRNA targeting survivin in 
transplanted tumors: Advances in Therapeutics., v. 26, p. 99-106. 
32. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., and zur Hausen, H., 2004, 
Classification of papillomaviruses: Virology, v. 324, p. 17-27. 
33. DeMasi, J., Chao, M. C., Kumar, A. S., and Howley, P. M., 2007, Bovine papillomavirus E7 
oncoprotein inhibits anoikis: Journal of Virology., v. 81, p. 9419-9425. 
34. Ding, Q., Bramble, L., Yuzbasiyan-Gurkan, V., Bell, T., and Meek, K., 2002, DNA-PKcs 
mutations in dogs and horses: allele frequency and association with neoplasia: Gene, v. 283, p. 
263-269. 
35. Duan, W. R., Garner, D. S., Williams, S. D., Funckes-Shippy, C. L., Spath, I. S., and 
Blomme, E. A., 2003, Comparison of immunohistochemistry for activated caspase-3 and cleaved 
cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of 
PC-3 subcutaneous xenografts: Journal of Pathology, v. 199, p. 221-228. 
36. Erk, N., 1976, A study of Kitab al-Hail wal-Biatar, written in the second half of the ninth 
century by Muhammed Ibn ahi Hizam: History of Veterinary Medicine, v. 1, p. 101-104. 
37. Evans, V. 2003 Canadian Equine Industry Profile Study. Strategic Equine Marketing.  9-26. 
2003.  Equine Canada.  
38. Foy, J. M., Rashmir-Raven, A. M., and Brashier, M. K., 2002, Common equine skin tumors: 
Compendium on Continuing Education for the Practicing Veterinarian, v. 24, p. 242-254. 
39. Fretz P.B. and Barber S.M., 1980, Prospective analysis of cryosurgery as the sole treatment 
for equine sarcoids Veterinary Clinics of North America: Small Animal Practice: p. 847-859. 
40. Frost, M., Jarboe, E. A., Orlicky, D., Gianani, R., Thompson, L. C., Enomoto, T., and 
Shroyer, K. R., 2002, Immunohistochemical localization of survivin in benign cervical mucosa, 
cervical dysplasia, and invasive squamous cell carcinoma: American Journal of Clinical 
Pathology, v. 117, p. 738-744. 
86 
 
41. Gerber, H., Dubath, M. L., and Lazary, S. Association between predisposition to equine 
sarcoid and MHC in multiple case families. Powell, D. G. Equine Infectious Diseases- 
Proceedings of the Fifth International Conference 5, 272-277. 1988.  University of Kentucky 
Press.  
42. Gobeil, P., Gault, E. A., Campo, M. S., Gow, J., Morgan, I. M., and Nasir, L., 2007, Equine 
sarcoids are not induced by an infectious cell line: Equine Veterinary Journal, v. 39, p. 189-191. 
43. Goodrich, L., Gerber, H., Marti, E., and Antczak, D. F., 1998, Equine sarcoids: Veterinary 
Clinics of North America Equine Practise, v. 14, p. 607-23, vii. 
44. Gown, A. M. and Willingham, M. C., 2002, Improved detection of apoptotic cells in archival 
paraffin sections: immunohistochemistry using antibodies to Cleaved Caspase 3: Journal of 
Histochemistry and Cytochemistry, v. 50, p. 449-454. 
45. Haralambus, R., Klukowskarutzler, J., and Brandt, S., 2010, Intralesional bovine 
papillomavirus DNA loads reflect severity of equine sarcoid disease: Equine Veterinary Journal, 
v. 42, p. 327-331. 
46. Head, K. W., 1965, Some data concerning the distribution of skin tumors in domestic 
animals, in Rook, A. J. and Walton, G. S., editors, Comparative physiology and pathology of the 
skin: Philadelphia, F.A. Davis, Co., p. 615. 
47. Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., and Korsmeyer, S. J., 1991, BCL2 
protein is topographically restricted in tissues characterized by apoptotic cell death.: Procedures 
of the National Academy Sciences U.S.A, v. 88, p. 6961-6965. 
48. Jackson, C., 1936, The incidence and pathology of tumours of domensticated animals in 
South Africa: The Onderstepoort Journal of Veterinary Science and Animal Industry, v. 6, p. 
375-385. 
49. Jackson, C., 1936, The mixed tumours: The Onderstepoort Journal of Veterinary Science: p. 
345-385. 
50. Johnson, M. E. and Howerth, E. W., 2004, Survivin: a bifunctional inhibitor of apoptosis 
protein: Veterinary Pathology, v. 41, p. 599-607. 
87 
 
51. Kemp-Symond, J. G., 2000, The detection and sequencing of bovine papillomavirus type 1 
and 2 DNA from Musca autumnalis face flies infesting sarcoid-affected horses: Royal Veterinary 
College, London, UK. 
52. Kidney, B. A. and Berrocal, A., 2008, Sarcoids in two captive tapirs (Tapirus bairdii): 
clinical, pathological and molecular study: Veterinary Dermatology, v. 19, p. 380-384. 
53. Kidney, B. A., Haines, D. M., Ellis, J. A., Burnham, M. L., Teifke, J. P., Czerwinski, G., and 
Jackson, M. L., 2001, Evaluation of formalin-fixed paraffin-embedded tissues from vaccine site-
associated sarcomas of cats for papillomavirus DNA and antigen: American Journal of 
Veterinary Research, v. 62, p. 833-839. 
54. Knottenbelt, D. C., 2005, A suggested clinical classification for the equine sarcoid: Clinical 
Techniques in Equine Practice, v. 4, p. 278-295. 
55. Knottenbelt, D. C., 2006, A suggested clinical classification for the Equine sarcoid: 
Pferdeheilkunde, v. 22, p. 479-480. 
56. Knottenbelt, D. C. and Kelly, D. F., 1995, The diagnosis and treatment of the equine sarcoid: 
In Practice, v. 17, p. 123-129. 
57. Korsmeyer, S. J., 1992, Bcl-2 initiates a new category of oncogenes: regulators of cell death: 
Blood, v. 80, p. 879-886. 
58. Lancaster, W. D., Olson, C., and Meinke, W., 1977, Bovine Papilloma virus: Presence of 
virus-specific DNA sequences in naturally occurring equine tumors: Procedures of National 
Academy Sciences USA, v. 74, p. 524-528. 
59. Landis, J. R. and Koch, G. G., 1977, The measurement of observer agreement for categorical 
data: Biometrics, v. 33, p. 159-174. 
60. Lazary, S., Gerber, H., Glatt, P. A., and Straub, R., 1985, Equine leukocyte antigens in 
sarcoid-affected horses: Equine Veterinary Journal, v. 17, p. 283-286. 
61. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., and Altieri, D. C., 
1998, Control of apoptosis and mitotic spindle checkpoint by survivin: Nature, v. 396, p. 580-
584. 
88 
 
62. Lohr, C. V., Juan-Salles, C., Rosas-Rosas, A., Paras, G. A., Garner, M. M., and Teifke, J. P., 
2005, Sarcoids in captive zebras (Equus burchellii): association with Bovine papillomavirus type 
1 infection: Journal of Zoo and Wildlife Medicine, v. 36, p. 74-81. 
63. Lu, Y. H., Wang, K., He, R., and Xi, T., 2008, Knockdown of Survivin and upregulation of 
p53 gene expression by small interfering RNA induces apoptosis in human gastric carcinoma 
cell line SGC-823: Cancer Biotherapy Radiopharmacology. 
64. Madewell, B. R., Candour-Edwards, R., Edwards, B. F., Walls, J. E., and Griffey, S. M., 
1999, Topographic distribution of Bcl-2 protein in feline tissues in health and neoplasia: 
Veterinary Pathology, v. 36, p. 565-573. 
65. Marais, H. J., Nel, P., Bertschinger, H. J., Schoeman, J. P., and Zimmerman, D., 2007, 
Prevalence and body distribution of sarcoids in South African Cape mountain zebra (Equus 
zebra zebra): Journal of the South African Veterinary Association-Tydskrif Van Die Suid-
Afrikaanse Veterinere Vereniging, v. 78, p. 145-148. 
66. Marchetti, B., Ashrafi, G. H., Tsirimonaki, E., O'Brien, P. M., and Campo, M. S., 2002, The 
bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and 
prevents their transport to the cell surface: Oncogene, v. 21, p. 7808-7816. 
67. Martens, A., De Moor, A., Demeulemeester, J., and Peelman, L., 2001, Polymerase chain 
reaction analysis of the surgical margins of equine sarcoids for Bovine papillomavirus DNA: 
Veterinary Surgery, v. 30, p. 460-467. 
68. Martens, A., De Moor, A., and Ducatelle, R., 2001, PCR detection of Bovine papillomavirus 
DNA in superficial swabs and scrapings from equine sarcoids: Veterinary Journal, v. 161, p. 
280-286. 
69. Martens, A., DeMoor A., Demeulemeester, J., and Ducatelle, R., 2000, Histopathological 
characteristics of five clinical types of equine sarcoid: Research in Veterinary Science, v. 69, p. 
295-300. 
70. Martens, A. and DeMoor, A., 1996, Equine sarcoid .1. Clinical types, prevalence, 
epidemiology, aetiology and pathogenesis: Vlaams Diergeneeskundig Tijdschrift, v. 65, p. 10-17. 
71. Marti, E., Lazary, S., Antczak, D. F., and Gerber, H., 1993, Report of the first international 
workshop on equine sarcoid: Equine Veterinary Journal, v. 25, p. 397-407. 
89 
 
72. Mattil-Fritz, S., Scharner, D., Piuko, K., Thones, N., Gissmann, L., Muller, H., and Muller, 
M., 2008, Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric 
papillomavirus-like particles: Journal of General Virology, v. 89, p. 138-147. 
73. Meredith, D., Elser, A. H., Wolf, B., Soma, L. R., Donawick, W. J., and Lazary, S., 1986, 
Equine leukocyte antigens: relationships with sarcoid tumors and laminitis in two pure breeds: 
Immunogenetics, v. 23, p. 221-225. 
74. Miller R.I. and Campbell R.S.F., 1982, A survey of granulomatous and neoplastic diseases of 
equine skin in north Queensland: Australian Veterinary Journal, v. 59, p. 33-37. 
75. Mohammed, H. O., Rebhun, W. C., and Antczak, D. F., 1992, Factors associated with the 
risk of developing sarcoid tumours in horses: Equine Veterinary Journal, v. 24, p. 165-168. 
76. Munday, J. S., Knight, C. G., and Howe, L., 2010, The same papillomavirus is present in 
feline sarcoids from North America and New Zealand but not in any non-sarcoid feline samples: 
Journal of Veterinary Diagnostic Investigation, v. 22, p. 97-100. 
77. Murakami, M., Sakai, H., Kodama, A., Mori, T., Maruo, K., Yanai, T., and Masegi, T., 2008, 
Expression of the anti-apoptotic factors Bcl-2 and survivin in canine vascular tumours: Journal 
of Comparative Pathology, v. 139, p. 1-7. 
78. Myers, R. K. and McGavin, M. D., 2007, Cellular and tissue repsonses to injury, in 
McGavin, M. D. and Zachary, J. F., editors, Pathologic Basis of Veterinary Disease: St. Louis, 
Missouri, Mosby Elsevier, p. 3-63. 
79. Nasir, L. and Campo, M. S., 2008, Bovine papillomaviruses: their role in the aetiology of 
cutaneous tumours of bovids and equids: Veterinary Dermatology, v. 19, p. 243-254. 
80. Nasir, L., Gault, E., Morgan, I. M., Chambers, G., Ellsmore, V., and Campo, M. S., 2007, 
Identification and functional analysis of sequence variants in the long control region and the E2 
open reading frame of bovine papillomavirus type 1 isolated from equine sarcoids: Virology, v. 
364, p. 355-361. 
81. Nasir, L. and Reid, S. W., 1999, Bovine papillomaviral gene expression in equine sarcoid 
tumours: Virus Research, v. 61, p. 171-175. 
90 
 
82. Nixon, C., Chambers, G., Ellsmore, V., Campo, M. S., Burr, P., Argyle, D. J., Reid, S. W., 
and Nasir, L., 2005, Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and 
p53 in equine sarcoids: Cancer Letters, v. 221, p. 237-245. 
83. Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., and 
Hase, T., 2000, Loop-mediated isothermal amplification of DNA: Nucleic Acids Research, v. 28, 
p. E63. 
84. Oaknin, A. and Barretina, M. P., 2008, Human papillomavirus vaccine and cervical cancer 
prevention: Clinical and Translational Oncology, v. 10, p. 804-811. 
85. Olson, C. and Cook, R. H., 1951, Cutaneous sarcoma-like lesions of the horse caused by the 
agent of Bovine papilloma: Proceedings of the Society of Expermental Biology and Medicine, v. 
77, p. 281-284. 
86. Olson, C. and Cook, R. H., 1951, Cutaneous sarcoma-like lesions of the horse caused by the 
agent of Bovine papilloma: Procedures of the Society Experimental Biology and Medicine, v. 77, 
p. 281-284. 
87. Otten, N., von, T. C., Lazary, S., Antczak, D. F., and Gerber, H., 1993, DNA of Bovine 
papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing: Archives 
of Virology, v. 132, p. 121-131. 
88. Pablos, J. L., Carreira, P. E., Serrano, L., Del Castillo, P., and Gomez-Reino, J. J., 1997, 
Apoptosis and proliferation of fibroblasts during postnatal skin development and scleroderma in 
the tight-skin mouse: Journal of Histochemistry and Cytochemistry, v. 45, p. 711-720. 
89. Pascoe, R. R. and Knottenbelt, D. C., 1999, Neoplastic Conditions. Manual of Equine 
Dermatology: London, WB Saunders, p. 244-250. 
90. Pascoe, R. R. and Summers, P. M., 1981, Clinical survey of tumours and tumour-like lesions 
in horses in south east Queensland: Equine Veterinary Journal, v. 13, p. 235-239. 
91. Petti, L. and DiMaio, D., 1994, Specific interaction between the bovine papillomavirus E5 
transforming protein and the beta receptor for platelet-derived growth factor in stably 
transformed and acutely transfected cells: Journal of Virology, v. 68, p. 3582-3592. 
91 
 
92. Petti, L., Nilson, L. A., and DiMaio, D., 1991, Activation of the platelet-derived growth 
factor receptor by the bovine papillomavirus E5 transforming protein: EMBO Journal, v. 10, p. 
845-855. 
93. Postey, R. C., Appleyard, G. D., and Kidney, B. A., 2007, Evaluation of equine papillomas, 
aural plaques, and sarcoids for the presence of Equine papillomavirus DNA and papillomavirus 
antigen: Canadian Journal of Veterinary Research-Revue Canadienne de Recherche Veterinaire, 
v. 71, p. 28-33. 
94. Ragland, W. L., Keown, G. H., and Spencer, G. R., 1970, Equine Sarcoid: Equine Veterinary 
Journal, v. 2, p. 2-11. 
95. Ragland, W. L., McLaughlin, C. A., and Spencer, G. R., 1970, Attempts to relate Bovine 
papillomavirus to the cause of equine sarcoid: horses, donkeys and calves inoculated wih equine 
sarcoid extracts: Equine Veterinary Journal, v. 2, p. 168-172. 
96. Ragland, W. L. and Spencer, G. R., 1969, Attempts to relate bovine papilloma virus to the 
cause of equine sarcoid: equidae inoculated intradermally with bovine papilloma virus: 
American Journal of Veterinary Research, v. 30, p. 743-752. 
97. Rebhun, R. B., Lana, S. E., Ehrhart, E. J., Charles, J. B., and Thamm, D. H., 2008, 
Comparative analysis of survivin expression in untreated and relapsed canine lymphoma: Journal 
of Veterinary Internal Medicine, v. 22, p. 989-995. 
98. Rector, A., Tachezy, R., Van Doorslaer, K., MacNamara, T., Burk, R. D., Sundberg, J. P., 
and Van Ranst, M., 2005, Isolation and cloning of a papillomavirus from a North American 
porcupine by using multiply primed rolling-circle amplification: the Erethizon dorsatum 
papillomavirus type 1: Virology, v. 331, p. 449-456. 
99. Reid, S. W., Gettinby, G., Fowler, J. N., and Ikin, P., 1994, Epidemiological observations on 
sarcoids in a population of donkeys (Equus asinus): Veterinary Record, v. 134, p. 207-211. 
100. Reid, S. W. and Mohammed, H. O., 1997, Longitudinal and cross-sectional studies to 
evaluate the risk of sarcoid associated with castration: Canadian Journal of Veterinary Research, 
v. 61, p. 89-93. 
101. Reimar, J., Muller, H., Rector, A., Van Ranst, M., and Stevens, H., 2009, Rolling-circle 
amplification of viral DNA genomes using phi29 polymerase: Trends in Microbiology, v. 17, p. 
205-211. 
92 
 
102. Resendes, A. R., Majo, N., Segals, J., Espadamala, J., Mateu, E., Chianini, F., Nofraras, M., 
and omingo, M., 2004, Apoptosis in normal lymphoid organs from healthy normal, conventional 
pigs at different ages detected by TUNEL and cleaved caspase-3 immunohistochemistry in 
paraffin-embedded tissues: Veterinary Immunology and Immunopathology, v. 99, p. 203-213. 
103. Schapiro, F., Sparkowski, J., Adduci, A., Suprynowicz, F., Schlegel, R., and Grinstein, S., 
2000, Golgi alkalinization by the papillomavirus E5 oncoprotein: Journal of Cell Biology, v. 
148, p. 305-315. 
104. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M., 1990, 
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation 
of p53: Cell, v. 63, p. 1129-1136. 
105. Scott D.W. and Miller W.H., 2003, Immune-Mediated Disorders. Equine Dermatology: St 
Louis, Missouri, Saunders, p. 475-547. 
106. Scott D.W. and Miller W.H., 2003, Neoplastic and non-neoplastic tumors. Equine 
Dermatology: St Louis, Missouri, Saunders, p. 719-731. 
107. Scott D.W. and Miller W.H., 2003, Skin Immune System and Allergic Skin Diseases. 
Equine Dermatology: St Louis, Missouri, Saunders, p. 395-474. 
108. Takai, N., Miyazaki, T., Nishida, M., Nasu, K., and Miyakawa, I., 2002, Survivin 
expression correlates with clinical stage, histological grade, invasive behavior and survival rate 
in endometrial carcinoma: Cancer Letters, v. 184, p. 105-116. 
109. Teifke, J. P., Hardt M., and Weiss, E., 1994, Detection of bovine papillomavirus DNA in 
formalin-fixed paraffin-embedded equine sarcoids by polymerase chain reaction and non-
radioactive in situ hybridization: European Journal of Veterinary Pathology, v. 1, p. 5-10. 
110. Teifke, J. P., Kidney, B. A., Lohr, C. V., and Yager, J. A., 2003, Detection of 
papillomavirus-DNA in mesenchymal tumour cells and not in the hyperplastic epithelium of 
feline sarcoids: Veterinary Dermatology, v. 14, p. 47-56. 
111. Teifke, J. P. and Weiss, E., 1991, Detection of Bovine Papillomavirus DNA in Equine 
Sarcoids by Polymerase Chain-Reaction (PCR): Berliner und Munchener Tierarztliche 
Wochenschrift, v. 104, p. 185-187. 
93 
 
112. Tomita, N., Mori, Y., Kanda, H., and Notomi, T., 2008, Loop-mediated isothermal 
amplification (LAMP) of gene sequences and simple visual detection of products: Nature 
Protocols, v. 3, p. 877-882. 
113. Tong, X. and Howley, P. M., 1997, The Bovine papillomavirus E6 oncoprotein interacts 
with paxillin and disrupts the actin cytoskeleton: Proceedings of National Academy Sciences 
USA, v. 94, p. 4412-4417. 
114. Torrontegui B.O. and Reid, S. W. J., 1994, Clinical and pathological epidemiology of the 
equine sarcoid in a referal population: Equine Veterinary Education, v. 6, p. 85-88. 
115. Valentine, B. A., 2006, Survey of equine cutaneous neoplasia in the Pacific Northwest: 
Journal of Veterinary Diagnostic Investigation, v. 18, p. 123-126. 
116. Voss, J. L., 1969, Transmission of equine sarcoid: American Journal of Veterinary 
Research, v. 30, p. 183-191. 
117. Wade, R., Brimer, N., and Vande, P. S., 2008, Transformation by bovine papillomavirus 
type 1 E6 requires paxillin: Journal of Virology, v. 82, p. 5962-5966. 
118. Werness, B. A., Levine, A. J., and Howley, P. M., 1990, Association of human 
papillomavirus types 16 and 18 E6 proteins with p53: Science, v. 248, p. 76-79. 
119. Wobeser, B. K., Davis, J. L., Hill, J. E., Jackson, M. L., Kidney, B. A., Mayer, M. N., 
Townsend, H. G. G., and Allen, A. L., 2010, Epidemiology of Equine Sarcoids in Horses in 
Western Canada. Canadian Veterinary Journal v.51, p.1103-1108.  
120. Wu, Y. H., You, Y., Chen, Z. C., and Zou, P., 2008, Reversal of drug resistance by 
silencing Survivin gene expression in acute myeloid leukemia cells: Acta Biochimica Polonica, 
v. 55, p. 673-680. 
121. Yaqin, M., Runhua, L., and Fuxi, Z., 2007, Analyses of Bcl-2, Survivin, and CD44v6 
expressions and human papillomavirus infection in cervical carcinomas: Scandavian Journal of 
Infectious Disease, v. 39, p. 441-448. 
122. Yuan, Z., Philbey, A. W., Gault, E. A., Campo, M. S., and Nasir, L., 2007, Detection of 
bovine papillomavirus type 1 genomes and viral gene expression in equine inflammatory skin 
conditions: Virus Research, v. 124, p. 245-249. 
94 
 
APPENDIX A. 
 
Data tables for matched equine skin samples for comparison of detection rate of BPV DNA from 
laser microdissected equine skin samples of sarcoid and non-sarcoid equine skin (Table 4.8). 
 
1. BPV DNA in neoplastic and non-neoplastic tissues 
 
This table shows the data used to generate the p value for comparison of BPV DNA detection 
rate from neoplastic tissue to the BPV DNA detection rate from non-neoplastic tissue (Table 4.8) 
in equine sarcoid skin samples.  Only skin samples where both neoplastic and non-neoplastic 
tissues were present were used for this comparison (n=65).   
 
  Neoplastic dermis Non-neoplastic 
dermis totals 
  Number of 
samples BPV 
Positive  
Number of 
samples BPV 
Negative 
 
     
Non-
neoplastic 
dermis 
Number of samples 
BPV Positive  
43 0 43 
Number of samples 
BPV Negative 
 
14 8 22 
 Neoplastic dermis 
totals 
57 8 65 
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2. BPV DNA in inflamed and non-inflamed epidermis 
 
This table shows the data used to generate the p value for comparison of BPV DNA detection 
rate from inflamed epithelium to the BPV DNA detection rate from non-inflamed epithelium in 
non-sarcoid equine skin samples (Table 4.8).  Only skin samples where both inflamed and non-
inflamed epitheliums were present were used for this comparison (n=25). 
 
 
 
 Inflamed epidermis Non-inflamed 
epidermis totals 
  Number of 
samples BPV 
Positive  
Number of 
samples BPV 
Negative 
 
     
Non-
inflamed 
epidermis 
Number of samples 
BPV Positive  
8 1 9 
Number of samples 
BPV Negative 
 
11 5 16 
 Inflamed epidermis 
totals 
19 6 25 
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3. BPV DNA in inflamed and non-inflamed dermis 
 
This table shows the data used to generate the p value for comparison of BPV DNA detection 
rate from inflamed dermis to the BPV DNA detection rate from non-inflamed dermis in non-
sarcoid equine skin samples (Table 4.8).  Only skin samples where both inflamed and non-
inflamed dermis were present were used for this comparison (n=26). 
 
 
 
 Inflamed dermis Non-inflamed 
dermis totals 
  Number of 
samples BPV 
Positive  
Number of 
samples BPV 
Negative 
 
     
Non-
inflamed 
dermis 
Number of samples 
BPV Positive  
5 0 5 
Number of samples 
BPV Negative 
 
9 12 21 
 Inflamed dermis 
totals 
14 12 26 
 
 
 
 
 
